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FIG. 17 (cont.)
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miR-29 (SEQ ID NO: 22)
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MICRO-RNA FAMILY THAT MODULATES
FIBROSIS AND USES THEREOF
CROSS-REFERENCE TO RELATED
APPLICATIONS
This application is a divisional of U.S. application Ser.
No. 13/840,896,filed Mar. 15, 2013, which is a continuation
of U.S. application Ser. No. 12/671,445, filed Jun. 25, 2010,
now U.S. Pat. No. 8,440,636, which is a national stage
application of International Application No. PCT/US2008/
071839, filed Jul. 31, 2008, which claims the benefit of U.S.
Provisional Application No. 60/952,917,filed Jul. 31, 2007;
USS. Provisional Application No. 60/980,303, filed Oct. 16,
2007, and U.S. Provisional Application No. 61/047,014,
filed Apr. 22, 2008, all of which are herein incorporated by
reference in their entireties.
STATEMENT OF GOVERNMENT SUPPORT
This invention was made with grant support under grant
no. HL53351-06 from the National Institutes of Health. The
governmenthas certain rights in the invention.
DESCRIPTION OF THE TEXT FILE
SUBMITTED ELECTRONICALLY
The contents of the text file submitted electronically
herewith are incorporated herein by reference in their
entirety: A computer readable format copy of the Sequence
Listing (filename: MIRG_005_09US_SeqList_ST25 txt,
date recorded: Jan. 7, 2015, file size 5 kilobytes).
FIELD OF THE INVENTION
The present invention relates generally to the fields of
developmental biology and molecular biology. More par-
ticularly, it concerns gene regulation and cellular physiology
in fibroblasts by the miR-29 family. This miRNA family
plays an important role in collagen deposition, particularly
collagen deposition mediated by fibroblasts.
BACKGROUND OF THE INVENTION
Heart disease and its manifestations, including coronary
artery disease, myocardial infarction, congestive heart fail-
ure and cardiac hypertrophy, clearly presents a major health
risk in the United States today. The cost to diagnose, treat
and support patients suffering from these diseases is well
into the billions of dollars. Two particularly severe mani-
festations of heart disease are myocardial infarction and
cardiac hypertrophy. With respect to myocardial infarction,
typically an acute thrombocytic coronary occlusion occurs
in a coronary artery as a result of atherosclerosis and causes
myocardial cell death. Because cardiomyocytes, the heart
muscle cells, are terminally differentiated and generally
incapable of cell division, they are generally replaced by
scar tissue when they die during the course of an acute
myocardial infarction. Scar tissue is not contractile, fails to
contribute to cardiac function, and often plays a detrimental
role in heart function by expanding during cardiac contrac-
tion, or by increasing the size and effective radius of the
ventricle, for example, becoming hypertrophic. Although
initial collagen deposition is required for infarct healing and
to prevent cardiac rupture, the continuous production of
collagen by fibroblasts inducesinterstitial fibrosis surround-
ing the myocytes in the infarct borderzone and remote
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myocardium of the infracted heart. This fibrosis induces
stiffness, diastolic dysfunction, and cardiomyocyte hyper-
trophy due to the increase in stress and can also lead to
arrythmias.
Cardiac hypertrophy is an adaptive response of the heart
to virtually all forms of cardiac disease, including those
arising from hypertension, mechanical load, myocardial
infarction, cardiac arrhythmias, endocrine disorders, and
genetic mutations in cardiac contractile protein genes. While
the hypertrophic responseis initially a compensatory mecha-
nism that augments cardiac output, sustained hypertrophy
can lead to dilated cardiomyopathy (DCM), heart failure,
and sudden death. In the United States, approximately half
a million individuals are diagnosed with heart failure each
year, with a mortality rate approaching 50%. The causes and
effects of cardiac hypertrophy have been extensively docu-
mented, but the underlying molecular mechanisms have not
been elucidated. Understanding these mechanismsis a major
concern in the prevention and treatment of cardiac disease
and will be crucial as a therapeutic modality in designing
new drugsthat specifically target cardiac hypertrophy and
cardiac heart failure.
Treatment with pharmacological agents represents the
primary mechanism for reducing or eliminating the mani-
festations of heart failure. Diuretics constitute the first line
of treatment for mild-to-moderate heart failure. If diuretics
are ineffective, vasodilatory agents, such as angiotensin
converting enzyme (ACE) inhibitors (e.g., enalopril and
lisinopril) or inotropic agent therapy (ie., a drug that
improves cardiac output by increasing the force of myocar-
dial muscle contraction) may be used. Unfortunately, many
of these standard therapies have numerous adverse effects
and are contraindicated in somepatients. Thus, the currently
used pharmacological agents have severe shortcomings in
particular patient populations. The availability of new, safe
and effective agents would undoubtedly benefit patients who
either cannot use the pharmacological modalities presently
available, or who do not receive adequate relief from those
modalities.
Cardiac myocytes are normally surrounded by a fine
network of collagen fibers. In response to pathological
stress, cardiac fibroblasts and extracellular matrix proteins
accumulate disproportionately and excessively. Myocardial
fibrosis, a characteristic of all forms of pathological hyper-
trophy, leads to mechanical stiffness, which contributes to
contractile dysfunction (Abraham et al., 2002). Another
hallmark of pathological hypertrophy andheart failureis the
re-activation of a set of fetal cardiac genes, including those
encoding atrial natriuretic peptide (ANP), B-type natriuretic
peptide (BNP) and fetal isoforms of contractile proteins,
such as skeletal a-actin and B-myosin heavy chain (MHC).
These genes are typically repressed post-natally and
replaced by the expression of a set of adult cardiac genes
(McKinsey and Olson, 2005). The consequences of fetal
gene expression on cardiac function and remodeling (e.g.,
fibrosis) are not completely understood. However, the up-
regulation of B-MHC, a slow ATPase, and down-regulation
of a-MHC,a fast contracting ATPase, in responseto stress
has been implicated in the diminution of cardiac function
(Bartel, 2004) and BNPis knownto play a dominantrole in
cardiac fibrosis.
In addition to cardiac fibrosis, there are a number of
disorders or conditions that are associated with fibrosis of
various tissues. Congenital hepatic fibrosis, an autosomal
recessive disease, is a rare genetic disease that affects both
the liver and kidneys. The disease is characterized by liver
abnormalities, such as hepatomegaly, portal hypertension,
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and fiber-like connective tissue that spreads over and
through the liver (hepatic fibrosis). Pulmonary fibrosis, or
scarring of the lung, results from the gradual replacementof
normal lung air sacs with fibrotic tissue. When the scar
forms, the tissue becomes thicker, causing an irreversible
loss of the tissue’s ability to transfer oxygen into the
bloodstream. The most current thinking is that the fibrotic
process in pulmonary tissue is a reaction (predisposed by
genetics) to microscopic injury to the lung. While the exact
cause remains unknown,associations have been made with
inhaled environmental and occupational pollutants, cigarette
smoking, diseases such as scleroderma, rheumatoidarthritis,
lupus andsarcoidosis, certain medications and therapeutic
radiation.
Scleroderma is a chronic disease characterized by exces-
sive deposits of collagen in the skin or other organs. The
localized type of the disease, while disabling, tends not to be
fatal. The systemic type or systemic sclerosis, which is the
generalized type of the disease, can be fatal as a result of
heart, kidney, lung or intestinal damage. Sclerodermaaffects
the skin, and in more serious cases it can affect the blood
vessels and internal organs.
Skeletal muscle fibrosis is a phenomenon which fre-
quently occurs in diseased or damaged muscle. It is char-
acterized by the excessive growth of fibrous tissue which
usually results from the body’s attempt to recover from
injury. Fibrosis impairs muscle function and causes weak-
ness. The extent of loss of muscle function generally
increases with the extent of fibrosis. Victims of muscular
dystrophies, particularly Becker muscular dystrophy (BMD)
and the more severely penetrating allelic manifestation,
Duchenne muscular dystrophy (DMD), frequently suffer
from increasing skeletal muscle fibrosis as the disease
progresses. Otherafflictions such as denervation atrophy are
known to produce skeletal muscle fibrosis, as well as neu-
romuscular diseases, such as acute polyneuritis, poliomy-
elitis, Werdig/Hoffman disease, amyotrophic lateral sclero-
sis (Lou Gehrig’s Disease), and progressive bulbar atrophy
disease.
MicroRNAshaverecently been implicated in a number of
biological processes including regulation of developmental
timing, apoptosis, fat metabolism, and hematopoietic cell
differentiation among others. MicroRNAs (miRs) are small,
non-protein coding RNAsof about 18 to about 25 nucleo-
tides in length that are derived from individual miRNA
genes, from introns of protein coding genes, or from poly-
cistronic transcripts that often encode multiple, closely
related miRNAs. See review of Carrington et al. (2003).
MiRsact as repressors of target mRNAsby promoting their
degradation, when their sequencesare perfectly complemen-
tary, or by inhibiting translation, when their sequences
contain mismatches.
miRNAsaretranscribed by RNA polymeraseII (pol II) or
RNApolymeraseIII (polIII; see Qi et al. (2006) Cellular &
Molecular Immunology Vol. 3:411-419) and arise from
initial transcripts, termed primary miRNAtranscripts (pri-
miRNAs), that are generally several thousand bases long.
Pri-miRNAs are processed in the nucleus by the RNase
Drosha into about 70- to about 100-nucleotide hairpin-
shaped precursors (pre-miRNAs). Following transport to the
cytoplasm, the hairpin pre-miRNA is further processed by
Dicer to produce a double-stranded miRNA. The mature
miRNAstrand is then incorporated into the RNA-induced
silencing complex (RISC), where it associates with its target
mRNAsbybase-pair complementarity. In the relatively rare
cases in which a miRNAbasepairs perfectly with an mRNA
target, it promotes mRNA degradation. More commonly,
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miRNAs form imperfect heteroduplexes with target
mRNAs, affecting either mRNA stability or inhibiting
mRNAtranslation.
The 5' portion ofamiRNAspanningbases 2-8, termed the
‘seed’ region, is especially important for target recognition
(Krenz and Robbins, 2004; Kiriazis and Krania, 2000). The
sequence of the seed, together with phylogenetic conserva-
tion of the target sequence, forms the basis for many current
target prediction models. Although increasingly sophisti-
cated computational approaches to predict miRNAs and
their targets are becoming available, target prediction
remains a major challenge and requires experimental vali-
dation. Ascribing the functions of miRNAsto the regulation
of specific mRNA targets is further complicated by the
ability of individual miRNAsto base pair with hundreds of
potential high and low affinity mRNAtargets and by the
targeting of multiple miRNAs to individual mRNAs.
Enhanced understanding of the functions of miRNAs will
undoubtedly reveal regulatory networks that contribute to
normal development, differentiation, inter- and intra-cellular
communication, cell cycle, angiogenesis, apoptosis, and
many other cellular processes. Recently, the inventors
reported a cardiac-specific microRNA, miR-208, which is
encoded by an intron of the a-myosin heavy chain (MHC)
gene,andis required for up-regulation of }-MHCexpression
in response to cardiac stress and for repression of fast
skeletal muscle genes in the heart (see co-pending applica-
tion WO2008/016924, which is herein incorporated byref-
erence in its entirety). The present invention expands on the
involvement of microRNAsin the heart as well as other
tissues.
SUMMARY OF THE INVENTION
The present invention is based on the discovery that the
miR-29 family, which is down-regulated in the heart in
response to stress, regulates collagen deposition and the
development of fibroses, including cardiac fibrosis. Up-
regulation ofmiR-29a-c expression or function results in the
decrease of expression of collagen andfibrin genes leading
to reduced cardiac fibrosis. Accordingly, the present inven-
tion provides a method oftreating cardiac fibrosis, cardiac
hypertrophy, or heart failure in a subject in need thereof
comprising identifying a subject having cardiac fibrosis,
cardiac hypertrophy or heart failure; and administering to
said subject an agonist of miR-29a-c expression or function.
In one embodiment, the agonist of miR-29a-c is a poly-
nucleotide comprising the mature sequence of miR-29a,
miR-29b, miR-29c, or combinations thereof. The agonist of
miR-29a-c may be administered by parenteral administra-
tion (e.g. intravenous or subcutaneous), oral, transdermal,
sustained release, controlled release, delayed release, sup-
pository, catheter or sublingual administration. In another
embodiment, the method further comprises administering to
the subject a second therapy. The secondtherapy is selected
from the group consisting of a beta blocker, an ionotrope, a
diuretic, ACE-I, All antagonist, BNP, a Ca**-blocker, an
endothelin receptor antagonist, and an HDAC inhibitor.
The present invention also provides a methodofprevent-
ing pathologic hypertrophy or heart failure in a subject in
need thereof comprising identifying a subject at risk of
developing pathologic cardiac hypertrophy or heart failure;
and promoting the expression or activity of miR-29a-c in
cardiac cells of said subject. In one embodiment, the pro-
moting expressionoractivity ofmiR-29a-c comprises deliv-
ering to the cardiac cells an agonist of miR-29a-c or an
expression vector encoding miR-29a-c. In another embodi-
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ment, the subject at risk exhibits one or more risk factors
selected from the group consisting of long standing uncon-
trolled hypertension, uncorrected valvular disease, chronic
angina, recent myocardial infarction, congenital predisposi-
tion to heart disease, and pathological hypertrophy. In
another embodiment, the subject at risk has been diagnosed
as having a genetic predisposition to cardiac hypertrophy. In
still another embodiment, the subject at risk has a familial
history of cardiac hypertrophy.
The present invention also encompasses a transgenic,
non-human mammal, the cells of which fail to express a
functional miR-29a, miR29b, and/or miR29c. In another
embodiment, the invention provides a transgenic, non-hu-
man mammal, the cells of which comprise a miR-29a-c
coding region under the control of a heterologous promoter
active in the cells of said non-human mammal. Thetrans-
genic mammal may be a mouse.
In one embodiment, the present invention provides a
methodoftreating myocardial infarction in a subject in need
thereof comprising promoting expression or activity of
miR-29a-c in cardiac cells of said subject. In another
embodiment, the present invention provides a method of
preventing cardiac hypertrophy and dilated cardiomyopathy
in a subject in need thereof comprising promoting expres-
sion or activity of miR-29a-c in cardiac cells of said subject.
In another embodiment, the present invention provides a
methodof inhibiting progression of cardiac hypertrophy in
a subject in need thereof comprising promoting expression
or activity of miR-29a-c in cardiac cells of said subject.
The present invention also contemplates a method of
treating or preventing a tissue fibrosis in a subject compris-
ing identifying a subject having orat risk of tissue fibrosis;
and increasing the expression and/or activity of miR-29a-c
in skeletal muscle or fibroblast cells of the subject. The
tissue fibrosis may be cardiac fibrosis, scleroderma, skeletal
muscle fibrosis, hepatic fibrosis, kidney fibrosis, pulmonary
fibrosis, or diabetic fibrosis. In some embodiments, increas-
ing the expression and/or activity of miR-29a-c comprises
administering an agonist of miR-29a-c to the subject. An
agonist of miR-29a-c may be a polynucleotide comprising
the sequence of a mature miR-29a, miR-29b, and/or miR-
29c¢ sequence. The agonist of miR-29a-c may also be an
expression vector encoding miR-29a, miR-29b, and/or miR-
29c. In one embodiment, the method further comprises
administering a non-miR-29a-c anti-fibrotic therapy to the
subject.
The present invention also provides a method for identi-
fying a modulator ofmiR-29a-c comprising contacting a cell
with a candidate compound; assessing miR-29a-c activity or
expression; and comparing the activity or expression in step
(b) with the activity or expression of miR-29a-c in the
absence of the candidate compound, wherein a difference
between the measured activities or expression of miR-29a-c
indicates that the candidate compound is a modulator of
miR-29. The cell may be contacted with the candidate
compoundin vitro or in vivo. Suitable candidate compounds
include proteins, peptides, polypeptides, polynucleotides,
oligonucleotides or small molecules.
Thepresent invention also encompasses a pharmaceutical
composition comprising an agonist or antagonist of miR-
29a-c. In some embodiments, the pharmaceutical composi-
tion may be formulated for injection or topical administra-
tion. The formulation for topical administration may be a
gel, cream, lotion, or ointment.
The present invention provides a method of inducing
collagen deposition in a tissue comprising contacting said
tissue with an antagonist of miR-29a-c. The antagonist may
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be an antagonist of miR-29a, miR-29b, or miR-29c. The
antagonist may be an antagomir of miR-29a-c, an antisense
oligonucleotide that targets a mature miR-29a-c sequence,
or an inhibitory RNA molecule, such as a siRNA or shRNA,
that comprises a sequence identical to a mature miR-29a-c
sequence, or a ribozyme or another inhibitory nucleic acid.
In one embodiment, the method further comprises contact-
ing said tissue with a second agent. The second agent may
be topical vitamin A, topical vitamin C, or vitamin E. In
another embodiment, the method further comprises subject-
ing said tissue to a second treatment, such as a chemical
peel, laser treatment, dermaplaning, or dermabrasion. In
another embodiment, the tissue is in a subject that suffers
from Ehler’s-Danlos syndrome or Vitamin C deficiency.
BRIEF DESCRIPTION OF THE DRAWINGS
The invention may be better understood by reference to
one or more of these drawings in combination with the
detailed description of specific embodiments presented
herein.
FIG. 1. miR-208 is encoded by the a-MHCgeneandis
expressed specifically in the heart. (Panel A) miR-208 is
encoded within an intron of the a-MHCgene. Asterisks
indicate sequence conservation (SEQ ID NOS:1-5). (Panel
B) Detection of miR-208 transcripts by Northern analysis of
adult mouse tissues. U6 mRNAservesas a loading control.
FIGS. 2A-B. Regulation of a- and B-MHC. (FIG. 2A)
Regulation of class switch by thyroid hormone and TRE.
(FIG. 2B) Model for stress/hypothyroidism in fast-to-slow
muscle fiber contactility switch.
FIG. 3. Detection of miR-208 in humanheart. Transcripts
for a-MHC and miR-208 were detected by Northern blot of
cardiac tissue from six normal individuals and six individu-
als with idiopathic cardiomyopathy. A close correlation
exists between the level of expression of a-MHC and
pre-miR-208, whereas mature miR-208 expression is main-
tained after the latter has been down-regulated.
FIG. 4. Generation of miR-208 mutant mice. (Panel A)
Strategy to generate miR-208 mutant mice by homologous
recombination. The pre-miRNA sequence (located within
intron 29 ofthe mouse a-MHCgenein mosttranscripts) was
replaced with a neomycin resistance cassette flanked by loxP
sites. The neomycin cassette was removed in the mouse
germline by breeding heterozygous mice to transgenic mice
harboring the CAG-Cre transgene. (Panel B) Detection of
miR-208 transcripts by Northern analysis of hearts from
wild-type and miR-208 mutant mice.
FIG. 5. Western analysis of a-MHC and B-MHCprotein
levels in hearts of neonatal mice of the indicated genotypes.
Two mice of each genotype were analyzed. GAPDH was
detected as a loading control.
FIG. 6. MiR-208~~ mice show reduced cardiac hypertro-
phy in response to pressure overload. Histological sections
of hearts of wild-type and miR-208- mice stained for
Masson trichrome. The absence of miR-208 diminishes
hypertrophy andfibrosis seen in wild-type mice subjected to
thoracic aortic banding (TAB) for 21 days. Scale bar equals
2 mm in top panel and 20 um for bottom panel.
FIG. 7. MiR-208~~ mice show reduced cardiac hypertro-
phy in response to calcineurin activation. Histological sec-
tions of hearts of 6 week-old mice expressing a calcineurin
transgene (CnA-Tg) and hearts of miR-208-"; CnA-Tg
stained for Masson trichrome. Absence of miR-208 dimin-
ishes hypertrophy and fibrosis seen in CnA-Tg mice. Scale
bar=2 mm for top panel, 20 um for bottom panel.
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FIG. 8. Mir-208-" mice fail to up-regulate B-MHC in
response to TAB andcalcineurin activation.
FIG. 9. Western analysis of a and B-MHCprotein levels
in adult wild-type and miR-208 transgenic animals. GAPDH
was detected as a loading control.
FIG. 10. miR-208-mice fail to up-regulate B-MHC in
response to hypothyroidism with PTU treatment.
FIG. 11. Schematic diagram of the role of miR-208 in the
control of B-MHC expression.
FIG. 12. Schematic diagram of the role of miR-208 in the
regulation of B-MHC and fast skeletal muscle gene expres-
sion via Thrap1.
FIG. 13. Mechanisms of action of microRNAs during
cardiac hypertrophy.
FIGS. 14A-C. miRNA expression during cardiac hyper-
trophy and remodeling. (FIG. 14A) H&Estained sections of
representative hearts from mice following sham and TAB for
21 days and from CnA Tg mice. Scale bar equals 2 mm.
(FIG. 14B) Venn diagrams showing numbers ofmicroRNAs
that changed in expression in each type of heart are shown
below. (FIG. 14C) Northern blots ofmicroRNAsthat change
in expression during hypertrophy. U6 RNA wasdetected as
a loading control.
FIG. 15. miR-29a-c expression is down-regulated in
responseto cardiac stress. Hearts from wild-type mice (WT)
and mice with hypertrophy and fibrosis induced by a cal-
cineurin transgene (CnA) or TAB are shown ontheleft. The
relative level of expression of miR-29a-c in each type of
heart is shown on the right.
FIG. 16. Microarray analysis of hearts from miR-208
knockout mice compared to wild-type. Microarray analysis
was performed on mRNA isolated from wild-type and
miR-208-null hearts at 6 weeks of age. The most down-
regulated miRNA, next to miR-208, is miR-499.
FIG. 17. miR-29 family is dramatically up-regulated in
miR-208-null hearts.
FIG. 18. miR-29 family targets mRNAs encoding colla-
gens and other components of the extracellular matrix
involved in fibrosis. Based on their high sequence homol-
ogy, the miR 29 family consists of 4 members; miR-29a,
miR29b-1 and -2 and miR-29c. The sequences of the mature
miRNAs are shown (SEQ ID NOS:18-20). The mature
sequences of miR-29b-1 and miR-29b-2 are identical.
Togetherthis family is directed against many components of
the extracellular matrix involved in fibrosis.
FIG. 19. Model for the control of cardiac fibrosis by
miR-208 and miR-29 family. In the normal heart, miR-208
inhibits the expression of miR-29a-c. In the absence of
miR-208, miR-29a-c expression is up-regulated, preventing
the expression of extracellular matrix and fibrosis in
response to stress. The functions of miR-208, miR-499 and
miR-29 are interlinked. Loss of miR-208 can be cardiopro-
tective by preventing expression of miR-499 and up-regu-
lating expression ofmiR-29a-c, with consequent blockade to
fibrosis.
FIGS. 20A-D. miR-29a-c regulates the expression of
extracellular matrix proteins. (FIG. 20A) Potential binding
sites for miR-29a-c in 3' UTRregionsof keyfibrotic genes.
(FIG. 20B) Real-time PCR analysis ofpredicted target genes
in both the borderzone and remote myocardium 3 days after
MI, shows a decrease in miR-29a-c to correlate to an
increase in collagens (COL1A1, COL1A2 and COL3A1)
and fibrillin (FBN1), while there was no significant change
in elastin (ELN1). (FIG. 20C) Northern blot analysis on
COScells transfected with increasing amounts of the CMV
expression plasmid encoding the miR-29b-1/miR-29a clus-
ter, showsefficient overexpression of miR-29a-b. The top
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band corresponds to the pre-miRNA, while the lower band
corresponds to the mature miRNA.(FIG. 20D) Luciferase
experiments using the endogenous UTR sequences of the
predicted target genes, showing miR-29a-c to repress
expression of luciferase in response to increasing amounts of
miR-29a-c while this decrease was absent when using an
unrelated miR, miR-206.
FIGS. 21A-B. miR-29a-c expression responsive to TGFB.
(FIG. 21A) Real-time PCR analysis indicates that all three
miR-29 family members are downregulated in fibroblasts in
response to TGF. (FIG. 21B) Northern analysis showing
miR-29a-c expression is upregulated in miR-208 mutant
animals which coincides with an increase in BNP expression
as determined by real-time PCR.
FIGS. 22A-G. miR-29a-c inhibition induces fibrosis in
vivo. (FIG. 22A) Chemical structure of anti-miR-29a-c and
mismatch (mm) miR-29a-c. (FIG. 22B) Northern blot analy-
sis showing tissue specific knockdown after 3 days in
response to intravenous injection of 80 mg/kg of either
anti-miR-29a-c or mm miR-29a-c or a comparable volume
of saline. (FIG. 22C) Real-time PCR analysis of liver
extracts indicate a pronounced increase in collagen expres-
sion in response to miR-29a-c knockdown,while this effect
was absentafter saline or mm injection. (FIG. 22D) Tissue
collection, three weeks after intravenous injection with 80
mg/kg on two consecutive days of either anti-miR-29a-c or
mm miR-29a-c oligonucleotide or a comparable volume of
saline, indicates a severe knockdown of miR-29a-c in heart,
liver and kidney, while miR-29a-c levels in lungs appear
unaffected. (FIG. 22E) Real-time PCR analysis of heart
extracts indicate a increase in cardiac collagen expression in
response to miR-29a-c knockdown. (FIG. 22F) Real-time
PCR analysis indicating an increase in miR-29b expression
in fibroblasts two days after miR-29b mimic treatment,
while miR-29a levels were unchanged and miR-29c levels
only slightly increased. (FIG. 22G) miR-29b overexpression
in fibroblasts represses the expression of collagen genes as
determined by real-time PCR analysis.
FIG. 23. Expression of miR-29 family members in vari-
ous tissues in response to miR-29b knockdown. Knockdown
of all miR-29 membersin the different tissues indicates that
miR-29b shows a 50% reduction in the heart in response to
anti-miR-29b, while miR-29a and -c only show marginal
changes. However, the knockdown of miR-29b in liver and
kidney in response to anti-miR-29b is almost complete,
while miR-29a and -c also appear to be reduced in these
tissues in response to anti-miR-29b.
DETAILED DESCRIPTION OF ILLUSTRATIVE
EMBODIMENTS
Cardiac and skeletal muscles respond to a variety of
pathophysiological stimuli such as workload, thyroid hor-
monesignaling and injury by modulating the expression of
myosin isoforms, which regulate the efficiency of contrac-
tion. Recently, the inventors reported a cardiac-specific
microRNA, miR-208, which is encoded by an intron of the
a-myosin heavy chain (MHC) gene, and is required for
up-regulation of B-MHC expression in response to cardiac
stress and for repression of fast skeletal muscle genes in the
heart (see co-pending application WO2008/016924, which
is herein incorporated by reference in its entirety).
Here, the inventors extend their earlier work and show
that miR-208 also down-regulates a family of related miR-
NAs, miR-29a-c. Because miR-29a-c are expressed ubiqui-
tously, and are involved in regulation of collagen deposition,
strategies to upregulate miR-29a-c expression have applica-
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tions in the prevention of a variety oftissue fibroses includ-
ing cardiac fibrosis, as well as skeletal muscle, liver, pul-
monary, diabetic and kidney fibrosis. Regulation of miR-
29a-c in cardiac cells, such as cardiac fibroblasts, can be
used to treat or prevent cardiac hypertrophy or heart failure
in a subject. Thus, one aspect of the invention is agonism of
miR-29a-c expression or activity, optionally in conjunction
with inhibiting miR-208. Agonism mayinvolve introducing
exogenous miR-29a-c into the heart or other tissues of
interest, either directly using naked nucleic acid or a delivery
vehicle such as a lipid/liposome/nanoparticle, or through
gene expression, for example by using adenoviral vectors or
other means of ectopic expression to reduce fibrosis. Acti-
vation of the anti-fibrotic function of miR-29a-c through
pharmaceutical “small molecules” also is contemplated, as
are screens to identify such compounds.
The increase in collagen that ensues following repression
of miR-29a-c expression, for example, following myocar-
dial infarction (MI) and other forms of stress, may indicate
another role for miR-29a-c. One focus of the inventors’
work is cardiac fibrosis, and an examination of a subset of
key regulatory genes, namely collagen I, III, elastin and
fibrillin, showed a striking increase in both collagens and
fibrillin in response to miR-29a-c downregulation, while
there was no increase in elastin. As such, therapeutically
repressing miR-29a-c to increase collagen deposition pres-
ents a unique option for addressing conditions characterized
by loss of collagen, such as in cosmetic applications and
scarring.
MicroRNA 29 (miR-29) is a family of microRNAsthat
consists of 4 known members, miR-29a, b1 and 2 (identical)
and c. While miR29b-1 and 29a stem from the same
transcript originating from chromosome 7 in humans and
chromosome 6 in mice, the miRNA cluster containing
miR29b-2 and miR29cis transcribed from chromosome1 in
both species. The mature miRNA sequences for each of the
human miR-29 family membersis listed below:
hsa-miR-29a
(SEQ ID NO: 18)
uagcaccaucugaaaucgguua
hsa-miR-29b-1 and b-2
(SEQ ID NO: 19)
uagcaccauuugaaaucaguguu
hsa-miR-29¢
(SEQ ID NO: 20)
uagcaccauuugaaaucgguua
These microRNAsform a family based on their sequence
homology (Yu et al; 2006). Since there are only minor
differences between the family members, and the members
have a 100% conserved seed region (which helps to define
target determination), they are very likely to target the same
mRNAtargets (FIG. 18), and lower gene expression ofthese
specific target genes. Target determination for the miR-29
family revealed that the miR-29 family showsa high pref-
erence for targeting genes involved in collagen formation as
well as other extracellular matrix proteins, such as elastin
(ELN), fibrillin 1 (FBN1), collagen type I, al and a2
(COLIA1, COL1A2) collagen type IJ, al (COL3A1),
metallopeptidases, and integrins. In responseto pathological
stress, cardiac fibroblasts and extracellular matrix proteins
accumulate disproportionately and excessively. Myocardial
fibrosis, a characteristic of all forms of pathological hyper-
trophy, leads to mechanical stiffness, which contributes to
contractile dysfunction (Berket al., 2007). Since the miR-29
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family is downregulated during this remodeling process, this
family is likely to play an active role in the modulation of
collagen deposition, and thereby regulate cardiac fibrosis
and cardiac contractility, which secondarily can induce
hypertrophy and pathological remodeling.
As discussed previously, miR-208 appears to regulate
miR-29 expression as miR-29 is significantly up-regulated
in the hearts of mice lacking both copies of miR-208 (see
Example 1). Thus, modulation of miR-208 can affect the
expression of miR-29 as well as the expression of miR-29
target genes. MiR-208 is an intronic miRNAthatis located
within an intron of the a-MEW gene. The precise intron
location is dependent on the particular species and specific
transcript. For example, in humans, miR-208 is encoded
within the 28” intron of the a-MHCgene, while in mice,it
is encoded within the 29” intron. The pre-miRNA encoding
sequences for miR-208 for human, mouse, rat, and canine
are provided in SEQ ID NO:14, SEQ ID NO:15, SEQ ID
NO:16, SEQ ID NO:17, respectively. The mature miR-208
sequence is provided in SEQ ID NO:5. Like a-MHC,
miR-208 is expressed solely in the heart. (FIG. 1).
Human pre-miR-208 (SEQ ID NO: 14)
acegggegage ttttggceecg ggttatacct gatgetcacg
tataagacga gcaaaaagct tgttggtcag a
Mouse pre-miR-208 (SEQ ID NO: 15)
acgggtgage ttttggececg ggttatacct gactctcacg
tataagacga gcaaaaagct tgttggtcag a
Rat pre-miR-208 (SEQ ID NO: 16)
acgggtgage ttttggececg ggttatacct gactctcacg
tataagacga gcaaaaagct tgttggtcag a
Canine pre-miR-208 (SEQ ID NO: 17)
acgeatgage ttttggctcg ggttatacct gatgetcacg
tataagacga gcaaaaagct tgttggtcag a
Using the PicTar algorithm for the identification of
miRNAtargets (Krek et al., 2005), the inventors identified
thyroid hormonereceptor associated protein 1 (THRAP1) as
a predicted target for miR-208. THRAP1 3' UTR sequences
from human, chimp, mouse, rat, canine, chicken, fugu, and
zebrafish are provided in SEQ ID NO:6, SEQ ID NO:7, SEQ
ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11,
SEQ ID NO:12, and SEQ ID NO:13, respectively.
Human THRAP1 3'UTR (SEQ ID NO: 6)
uucuugcuuu aaagcaauug gucuaaaaua uauguaaucg
ucuuaauuaa aaaguugcag uaggguuge
Chimp THRAP1 3'UTR (SEQ ID NO: 7)
uucuugcuuu aaagcaauug gucuaaaaua uauguaaucg
ucuuaauuaa aacguugcag uaggguuge
Mouse THRAP1 3'UTR (SEQ ID NO:8)
uucuugcuuu aaagcaauug gucuaaaaua uauguaaucg
ucuuaauuaa aacguugcag uaggguuge
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Rat THRAP1 3'UTR (SEQ ID NO:9)
uucuugcuuu aaagcaauug gucuaaaaua uauguaaucg
ucuuaauuaa aacguugcag uaggguuge
Canine THRAP1 3'UTR (SEQ ID NO:10)
uucuugcuuu aaagcaauug gucuaaaaua uauguaaucg
ucuuaauuaa aacguugcag uaggguuge
Chicken THRAP1 3'UTR (SEQ ID NO:11)
uucuugcuuu aaagcaauug gucuaaaaua uauguaaucg
ucuuaauuaa aacguugcag uaggguuge
Fugu THRAP1 3'UTR (SEQ ID NO:12)
uuccugcuuu aagcaauugg uugaaaauau auguauguaa
uggucuuaau uaaaaaaaca aacuaagaca aa
Zebrafish THRAP1 3'UTR (SEQ ID NO:13)
uuccugcuuu aaagcaauug gucuaaaaua uauguaaucg
ucuucauuac aaaaacgaac caucaaacg
The present invention provides a method of treating
cardiac fibrosis, cardiac hypertrophy or heart failure in a
subject in need thereof comprising identifying a subject
having cardiac fibrosis, cardiac hypertrophy or heart failure;
and administering to the subject an agonist of miR-29
expression or function. The miR-29 agonist may be an
agonist of miR-29a, miR-29b and/or miR-29c.
In one embodiment, agonists of miR-29a-c may bepoly-
nucleotides comprising the mature miR-29a-c sequence. In
some embodiments, the polynucleotide comprises the
sequence of SEQ ID NO: 18, SEQ ID NO: 19, or SEQ ID
NO:20. In another embodiment, the agonist of miR-29a-c
may be a polynucleotide comprising the pri-miRNA or
pre-miRNA sequence for miR-29a, miR-29b, and/or miR-
29c. The polynucleotide comprising the mature miR-29a-c,
pre-miR-29a-c, or pri-miR-29a-c sequence may be single
stranded or double stranded. The polynucleotides may con-
tain one or more chemical modifications, such as locked
nucleic acids, peptide nucleic acids, sugar modifications,
such as 2'-O-alkyl (e.g. 2'-O-methyl, 2'-O-methoxyethyl),
2'-fluoro, and 4' thio modifications, and backbone modifi-
cations, such as one or more phosphorothioate, morpholino,
or phosphonocarboxylate linkages. In one embodiment, the
polynucleotide comprising a miR-29a-c sequence is conju-
gated to cholesterol. In another embodiment, the agonist of
miR-29a-c may be an agent distinct from miR-29a-c that
acts to increase, supplement, or replace the function of
miR-29a-c.
In another embodiment, the agonist of miR-29a-c may be
expressed in vivo from a vector. A “vector” is a composition
of matter which can be used to deliver a nucleic acid of
interest to the interior of a cell. Numerousvectors are known
in the art including, but not limited to, linear polynucle-
otides, polynucleotides associated with ionic or amphiphilic
compounds, plasmids, and viruses. Thus, the term “vector”
includes an autonomously replicating plasmid or a virus.
Examples of viral vectors include, but are not limited to,
adenoviral vectors, adeno-associated virus vectors, retrovi-
ral vectors, and the like. An expression construct can be
replicatedin a living cell, or it can be made synthetically. For
purposes of this application, the terms “expression con-
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struct,” “expression vector,” and “vector,” are used inter-
changeably to demonstrate the application of the invention
in a general, illustrative sense, and are not intended to limit
the invention.
In one embodiment, an expression vector for expressing
miR-29a-c comprises a promoter “operably linked” to a
polynucleotide encoding miR-29a, miR-29b, miR-29c, or
combinations thereof. In another embodiment, the poly-
nucleotide may encode the miR-29b-1/miR-29a cluster. In
another embodiment, the polynucleotide may encode the
miR-29b-2/miR-29c cluster. The phrase “operably linked”
or “undertranscriptional control” as used herein meansthat
the promoter is in the correct location and orientation in
relation to a polynucleotide to control the initiation of
transcription by RNA polymerase and expression of the
polynucleotide. The polynucleotide encoding miR-29a-c
may encode the primary-microRNA-29a-c sequence (pri-
miR-29a-c), the precursor-microRNA-29a-c sequence (pre-
miR-229a-c) or the mature miR-29a-c sequence. In another
embodiment, the expression vector comprises a polynucle-
otide operably linked to a promoter, wherein said polynucle-
otide comprises the sequence of SEQ ID NO:18. In another
embodiment, the expression vector comprises a polynucle-
otide operably linked to a promoter, wherein said polynucle-
otide comprises the sequence of SEQ ID NO: 19.In still
another embodiment, the expression vector comprises a
polynucleotide operably linked to a promoter, wherein said
polynucleotide comprises the sequence of SEQ ID NO:20.
The polynucleotide comprising the sequence of SEQ ID NO:
18, SEQ ID NO: 19, or SEQ ID NO: 20 may be about18 to
about 2000 nucleotides in length, about 70 to about 200
nucleotides in length, about 20 to about 50 nucleotides in
length, or about 18 to about 25 nucleotides in length.
Throughout this application, the term “expression con-
struct” is meant to include any type of genetic construct
containing a nucleic acid coding for a gene product in which
part or all of the nucleic acid encoding sequence is capable
of being transcribed. Generally, the nucleic acid encoding a
gene product is undertranscriptional control of a promoter.
A “promoter” refers to a DNA sequence recognized by the
synthetic machinery of the cell, or introduced synthetic
machinery, required to initiate the specific transcription of a
gene.
The term promoterwill be usedhere to refer to a group of
transcriptional control modules that are clustered around the
initiation site for a RNA polymerase. Much of the thinking
about how promoters are organized derives from analyses of
several viral promoters, including those for the HSV thy-
midine kinase (tk) and SV40 early transcription units. These
studies, augmented by more recent work, have shown that
promoters are composed of discrete functional modules,
each consisting of approximately 7-20 bp of DNA, and
containing one or more recognition sites for transcriptional
activator or repressor proteins.
At least one module in each promoter functions to posi-
tion the start site for RNA synthesis. The best known
example of this is the TATA box, but in some promoters
lacking a TATA box, such as the promoter for the mamma-
lian terminal deoxynucleotidyl transferase gene and the
promoter for the SV40 late genes, a discrete element over-
lying thestart site itself helps to fix the place of initiation.
Additional promoter elements regulate the frequency of
transcriptional initiation. Typically, these are located in the
region 30-110 by upstream of the start site, although a
number of promoters have recently been shown to contain
functional elements downstream ofthe start site as well. The
spacing between promoter elements frequently is flexible, so
29
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that promoter function is preserved when elements are
inverted or movedrelative to one another.In the tk promoter,
the spacing between promoter elements can be increased to
50 bp apart before activity begins to decline. Depending on
the promoter, it appears that individual elements can func-
tion either co-operatively or independently to activate tran-
scription.
In other embodiments, the human cytomegalovirus
(CMV) immediate early gene promoter, the SV40 early
promoter, the Rous sarcoma virus long terminal repeat, rat
insulin promoter, RNA pol III promoter, and glyceralde-
hyde-3-phosphate dehydrogenase promoter can be used to
obtain high-level expression of the polynucleotide of inter-
est. The use ofother viral or mammalian cellular or bacterial
phage promoters which are well-knownin the art to achieve
expression of a polynucleotide of interest is contemplated as
well, provided that the levels of expression are sufficient for
a given purpose.
By employing a promoter with well-knownproperties, the
level and pattern of expression of the polynucleotide of
interest following transfection or transformation can be
optimized. Further, selection of a promoterthat is regulated
in responseto specific physiologic signals can permit induc-
ible expression of the gene product. Tables 1 and 2 list
several regulatory elements that may be employed, in the
context of the present invention, to regulate the expression
of the gene of interest. This list is not intended to be
exhaustive of all the possible elements involved in the
promotion of gene expression but, merely, to be exemplary
thereof.
Enhancers are genetic elements that increase transcription
from a promoter located at a distant position on the same
molecule of DNA. Enhancers are organized much like
promoters. That is, they are composed of many individual
elements, each ofwhich binds to one or moretranscriptional
proteins.
The basic distinction between enhancers and promotersis
operational. An enhancer region as a whole must be able to
stimulate transcription at a distance; this need not be true of
a promoter region or its component elements. On the other
hand, a promoter must have one or more elements thatdirect
initiation of RNA synthesis at a particular site and in a
particular orientation, whereas enhancers lack these speci-
ficities. Promoters and enhancers are often overlapping and
contiguous, often seeming to have a very similar modular
organization.
Below is a list of viral promoters, cellular promoters/
enhancers and inducible promoters/enhancers that could be
used in combination with the nucleic acid encoding a gene
of interest in an expression construct (Table 1 and Table 2).
Additionally, any promoter/enhancer combination (as per
the Eukaryotic Promoter Data Base EPDB) could also be
used to drive expression of the gene. Eukaryotic cells can
support cytoplasmic transcription from certain bacterial pro-
moters if the appropriate bacterial polymerase is provided,
either as part of the delivery complex or as an additional
genetic expression construct. In a preferred embodiment, the
polynucleotide encoding the miR-29a-c or miR-29a-c
antagonist is operably-linked to a fibroblast specific pro-
moter.
 
TABLE 1
Promoter and/or Enhancer
Promoter/Enhancer References
Immunoglobulin Banerji et al., 1983; Gilles et al., 1983;
Heavy Chain Grossched| et al., 1985; Atchinson et al., 1986,
1987; Imler et al., 1987; Weinbergeret al., 1984;
Kiledjian et al., 1988; Porton et al.; 1990
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TABLE 1-continued
 
Promoter and/or Enhancer
Promoter/Enhancer References
Immunoglobulin Queen et al., 1983; Picard et al., 1984
Light Chain
T-Cell Receptor Luria et al., 1987; Winoto et al., 1989; Redondo
et al.; 1990
HLA DQ a and/or Sullivan et al., 1987DQ B
§-Interferon Goodbourn et al., 1986; Fujita et al., 1987;
Goodbourn et al., 1988
Interleukin-2 Greene et al., 1989
Interleukin-2 Greene et al., 1989; Lin et al., 1990
Receptor
MHCClass II 5 Koch etal., 1989
MHCClassII Sherman et al., 1989
HLA-DRa
f-Actin Kawamoto et al., 1988; Ng et al.; 1989
Muscle Creatine Jaynes et al., 1988; Horlick et al., 1989; Johnson
Kinase (MCK) et al., 1989
Prealbumin Costa et al., 1988
(Transthyretin)
Elastase I Ornitz et al., 1987
Metallothionein Karin et al., 1987; Culotta et al., 1989
(MTI)
Collagenase Pinkert et al., 1987; Angel et al., 1987a
Albumin Pinkert et al., 1987; Tronche et al., 1989, 1990
a-Fetoprotein Godboutet al., 1988; Campereet al., 1989
t-Globin Bodine et al., 1987; Perez-Stable et
al., 1990
6-Globin Trudel et al., 1987
c-fos Cohenet al., 1987
c-HA-ras Triesman, 1986; Deschampset al., 1985
Insulin Edlundet al., 1985
Neural Cell Hirsh et al., 1990
Adhesion Molecule
(NCAM)
a,-Antitrypain Latimeret al., 1990
H2B (TH2B) Histone Hwanget al., 1990
Mouse and/or Ripe et al., 1989
Type I Collagen
Glucose-Regulated Chang et al., 1989
Proteins (GRP94
and GRP78)
Rat Growth Hormone Larsenetal., 1986
Human Serum Edbrookeet al., 1989
Amyloid A (SAA)
Troponin I (TN I) Yutzey et al., 1989
Platelet-Derived Pech et al., 1989
Growth Factor
(PDGF)
Duchenne Muscular Klamutet al., 1990
Dystrophy
Sv40 Banerji et al., 1981; Moreau et al., 1981; Sleigh et
al., 1985; Firak et al., 1986; Herret al., 1986;
Imbra and Karin et al., 1986; Kadesch etal.,
1986; Wang et al., 1986; Ondek et al., 1987;
Kuhlet al., 1987; Schaffner et al., 1988
Polyoma Swartzendruberet al., 1975; Vasseur et al., 1980;
Katinka et al., 1980, 1981; Tyndell et al., 1981;
Dandolo et al., 1983; de Villiers et al., 1984; Hen
et al., 1986; Satake et al., 1988; Campbell and/or
Villarreal, 1988
Retroviruses Kriegler et al., 1982, 1983; Levinson et al., 1982;
Kriegler et al., 1983, 1984a, b, 1988; Boszeet al.,
1986; Miksicek et al., 1986; Celander et al., 1987;
Thiesen et al., 1988; Celanderet al., 1988; Choi
et al., 1988; Reisman et al., 1989
Papilloma Virus Campoet al., 1983; Lusky et al., 1983; Spandidos
and/or Wilkie, 1983; Spalholz et al., 1985; Lusky
et al., 1986; Cripe et al., 1987; Gloss et al.,
1987; Hirochika et al., 1987; Stephens et al., 1987
Hepatitis B Virus Bulla et al., 1986; Jameel et al., 1986;
Shaul et al., 1987; Spandauet al., 1988;
Vannice et al., 1988
Human Muesing et al., 1987; Hauberet al., 1988;
Immunodeficiency Jakobovits et al., 1988; Feng et al., 1988;
Virus Takebe et al., 1988; Rosen et al., 1988; Berkhout
et al., 1989; Laspia et al., 1989; Sharp et al.,
1989; Braddocket al., 1989
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TABLE 1-continued
 
Promoter and/or Enhancer
Promotetr/Enhancer References
Cytomegalovirus Weberet al., 1984; Boshart et al., 1985; Foecking
 
(CMV) et al., 1986
Gibbon Ape Holbrook et al., 1987; Quinn etal., 1989
Leukemia Virus
TABLE 2
Inducible Element:
Element Inducer References
MT II Phorbol Ester (TFA) Palmiter et al., 1982;
Heavy metals Haslinger et al., 1985;
Searle et al., 1985; Stuart
et al., 1985; Imagawa
et al., 1987, Karinet al.,
1987; Angel et al., 1987b;
McNeallet al., 1989
Huanget al., 1981; Lee et
al., 1981; Majors et al.,
1983; Chandleret al., 1983;
Ponta et al., 1985; Sakai
et al., 1988
MMTV(mouse Glucocorticoids
mammary
tumorvirus)
§-Interferon poly(@)x Tavernier et al., 1983
poly(re)
Adenovirus 5 E2 EIA Imperiale et al., 1984
Collagenase Phorbol Ester (TPA) Angelet al., 1987a
Stromelysin Phorbol Ester (TPA) Angelet al., 1987b
SV40 Phorbol Ester (TPA) Angelet al., 1987b
Murine MX Gene Interferon, Huget al., 1988
Newcastle
Disease Virus
GRP78 Gene A23187 Resendez et al., 1988
a-2-Macroglobulin IL-6 Kunzet al., 1989
Vimentin Serum Rittling et al., 1989
MHCClass I Gene Interferon Blanar et al., 1989
H-2kb
HSP70 EIA, SV40 Large Taylor et al., 1989, 1990a,
T Antigen 1990b
Proliferin Phorbol Ester-TPA Mordacqet al., 1989
Tumor Necrosis PMA Henselet al., 1989
Factor Thyroid
Stimulating
Hormone a@ Gene
Thyroid Hormone Chatterjee et al., 1989
 
Where a cDNAinsert is employed, one will typically
desire to include a polyadenylation signal to effect proper
polyadenylation of the gene transcript. The nature of the
polyadenylation signal is not believed to be crucial to the
successful practice of the invention, and any such sequence
may be employed such as human growth hormone and SV40
polyadenylation signals. Also contemplated as an element of
the expression cassette is a terminator. These elements can
serve to enhance message levels and to minimize read
through from the cassette into other sequences.
In certain embodiments of the invention, the cells con-
taining nucleic acid constructs of the present invention may
be identified in vitro or in vivo by including a marker in the
expression construct. Such markers would confer an iden-
tifiable change to the cell permitting easy identification of
cells containing the expression construct. Usually the inclu-
sion of a drug selection marker aids in cloning and in the
selection of transformants, for example, genes that confer
resistance to neomycin, puromycin, hygromycin, DHFR,
GPT, zeocin and histidinol are useful selectable markers.
Alternatively, enzymes such as herpes simplex virus thymi-
dine kinase(tk) or chloramphenicol acetyltransferase (CAT)
may be employed. Immunologic markers also can be
10
15
20
25
30
35
40
45
50
55
60
65
16
employed. The selectable marker employed is not believed
to be important, so long as it is capable of being expressed
simultaneously with the nucleic acid encoding a gene prod-
uct. Further examples of selectable markers are well known
to one of skill in the art.
There are a number of ways in which expression vectors
may introduced into cells. In certain embodiments of the
invention, the expression construct comprises a virus or
engineered construct derived from a viral genome. The
ability of certain virusesto enter cells via receptor-mediated
endocytosis, to integrate into host cell genome and express
viral genes stably andefficiently have made them attractive
candidates forthe transfer of foreign genes into mammalian
cells (Ridgeway, 1988; Nicolas and Rubenstein, 1988;
Baichwal and Sugden, 1986; Temin, 1986).
Oneofthe preferred methodsfor in vivo delivery involves
the use of an adenovirus expression vector. “Adenovirus
expression vector” is meant to include those constructs
containing adenovirus sequences sufficient to (a) support
packaging of the construct and (b) to express a polynucle-
otide that has been cloned therein. The expression vector
comprises a genetically engineered form of adenovirus.
Knowledge of the genetic organization of adenovirus, a 36
kB,linear, double-stranded DNAvirus, allows substitution
of large pieces of adenoviral DNAwith foreign sequences up
to 7 kB (Grunhaus and Horwitz, 1992). In contrast to
retrovirus, the adenoviral infection of host cells does not
result in chromosomal integration because adenoviral DNA
can replicate in an episomal manner without potential geno-
toxicity. Also, adenoviruses are structurally stable, and no
genome rearrangement has been detected after extensive
amplification. Adenovirus can infect virtually all epithelial
cells regardless of their cell cycle stage.
Adenovirus is particularly suitable for use as a gene
transfer vector because of its mid-sized genome, ease of
manipulation, high titer, wide target cell range and high
infectivity. Both ends of the viral genome contain 100-200
base pair inverted repeats (ITRs), which are cis elements
necessary for viral DNA replication and packaging.
Other than the requirement that the adenovirus vector be
replication defective, or at least conditionally defective, the
nature of the adenovirus vector is not believed to be crucial
to the successful practice of the invention. The adenovirus
may be of any of the 42 different known serotypes or
subgroups A-F. Adenovirus type 5 of subgroup C is the
preferred starting material in order to obtain the conditional
replication-defective adenovirus vector for use in the present
invention. This is because Adenovirus type 5 is a human
adenovirus about which a great deal of biochemical and
genetic information is known, andit has historically been
used for most constructions employing adenovirus as a
vector.
As stated above, the typical vector according to the
present invention is replication defective and will not have
an adenovirus E1 region. Thus,it will be most convenient to
introduce the polynucleotide encoding the gene ofinterest at
the position from which the E1-coding sequences have been
removed. However, the position of insertion of the construct
within the adenovirus sequencesis notcritical to the inven-
tion. The polynucleotide encoding the gene of interest may
also be inserted in lieu of the deleted E3 region in E3
replacement vectors, as described by Karlssonet al. (1986),
or in the E4 region where a helper cell line or helper virus
complements the E4 defect.
Adenovirus vectors have been used in eukaryotic gene
expression (Levrero et al., 1991; Gomez-Foix et al., 1992)
and vaccine development (Grunhaus and Horwitz, 1992;
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Graham and Prevec, 1991). Recently, animal studies sug-
gested that recombinant adenovirus could be used for gene
therapy (Stratford-Perricaudet and Perricaudet, 1991; Strat-
ford-Perricaudet et al., 1990; Rich et al., 1993). Studies in
administering recombinant adenovirus to different tissues
include trachea instillation (Rosenfeld et al., 1991; Rosen-
feld et al., 1992), muscle injection (Ragot et al., 1993),
peripheral intravenous injections (Herz and Gerard, 1993)
and stereotactic inoculation into the brain (Le Gal La Salle
et al., 1993).
Retroviral vectors are also suitable for expressing the
polynucleotides of the invention in cells. The retroviruses
are a group of single-stranded RNAviruses characterized by
an ability to convert their RNA to double-stranded DNA in
infected cells by a process of reverse-transcription (Coffin,
1990). The resulting DNA thenstably integrates into cellular
chromosomes as a provirus and directs synthesis of viral
proteins. The integration results in the retention of the viral
gene sequencesin the recipient cell and its descendants. The
retroviral genome contains three genes, gag, pol, and env
that code for capsid proteins, polymerase enzyme, and
envelope components, respectively. A sequence found
upstream from the gag gene contains a signal for packaging
of the genomeinto virions. Two long terminal repeat (LTR)
sequences are present at the 5' and 3' ends of the viral
genome. These contain strong promoter and enhancer
sequences and are also required for integration in the host
cell genome (Coffin, 1990).
In order to construct a retroviral vector, a nucleic acid
encoding a geneof interest is inserted into the viral genome
in the place of certain viral sequences to producea virusthat
is replication-defective. In order to produce virions, a pack-
aging cell line containing the gag, pol, and env genes but
without the LTR and packaging components is constructed
(Mann et al., 1983). When a recombinant plasmid containing
a cDNA,together with the retroviral LTR and packaging
sequences is introduced into this cell line (by calctum
phosphate precipitation for example), the packaging
sequence allows the RNAtranscript of the recombinant
plasmid to be packaged into viral particles, which are then
secreted into the culture media (Nicolas and Rubinstein,
1988; Temin, 1986; Mann et al., 1983). The media contain-
ing the recombinantretrovirusesis then collected, optionally
concentrated, and used for gene transfer. Retroviral vectors
are able to infect a broad variety of cell types. However,
integration and stable expression require the division of host
cells (Paskind et al., 1975).
Other viral vectors may be employed as expression con-
structs in the present invention. Vectors derived from viruses
such as vaccinia virus (Ridgeway, 1988; Baichwal and
Sugden, 1986; Couparet al., 1988) adeno-associated virus
(AAV) (Ridgeway, 1988; Baichwal and Sugden, 1986; Her-
monat and Muzycska, 1984) and herpesviruses may be
employed. They offer several attractive features for various
mammalian cells (Friedmann, 1989; Ridgeway, 1988;
Baichwal and Sugden, 1986; Coupar et al., 1988; Horwich
et al., 1990).
In order to affect expression of sense or antisense gene
constructs, the expression construct must be delivered into a
cell. This delivery may be accomplished in vitro, as in
laboratory procedures for transformingcells lines, or in vivo
or ex vivo, as in the treatment of certain disease states. One
mechanism for delivery is via viral infection where the
expression construct is encapsidated in an infectious viral
particle.
Several non-viral methods for the transfer of expression
constructs into cultured mammalian cells also are contem-
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plated by the present invention. These include calcium
phosphate precipitation (Graham and Van Der Eb, 1973;
Chen and Okayama, 1987; Rippe et al., 1990) DEAE-
dextran (Gopal, 1985), electroporation (Tur-Kaspa et al.,
1986; Potter et al., 1984), direct microinjection (Harland and
Weintraub, 1985), DNA-loaded liposomes (Nicolau and
Sene, 1982; Fraley et al., 1979) and lipofectamine-DNA
complexes, cell sonication (Fechheimer et al., 1987), gene
bombardmentusing high velocity microprojectiles (Yang et
al., 1990), and receptor-mediated transfection (Wu and Wu,
1987; Wu and Wu, 1988). Someofthese techniques may be
successfully adapted for in vivo or ex vivo use.
Once the expression construct has been delivered into the
cell the nucleic acid encoding the gene of interest may be
positioned and expressed at different sites. In certain
embodiments, the nucleic acid encoding the gene may be
stably integrated into the genomeofthe cell. This integration
may bein the cognate location and orientation via homolo-
gous recombination (gene replacement) or it may be inte-
grated in a random, non-specific location (gene augmenta-
tion). In yet further embodiments, the nucleic acid may be
stably maintained in the cell as a separate, episomal segment
of DNA.Such nucleic acid segments or “episomes” encode
sequences sufficient to permit maintenance and replication
independentofor in synchronization with the host cell cycle.
How the expression construct is delivered to a cell and
where in the cell the nucleic acid remains is dependent on
the type of expression construct employed.
In yet another embodiment of the invention, the expres-
sion construct may simply consist of naked recombinant
DNA or plasmids. Transfer of the construct may be per-
formed by any of the methods mentioned above which
physically or chemically permeabilize the cell membrane.
Thisis particularly applicable for transfer in vitro but it may
be applied to in vivo use as well. Dubenskyet al. (1984)
successfully injected polyomavirus DNA in the form of
calcium phosphate precipitates into liver and spleen of adult
and newborm mice demonstrating active viralreplication and
acute infection. Benvenisty and Neshif (1986) also demon-
strated that direct intraperitoneal injection of calcium phos-
phate-precipitated plasmids results in expression of the
transfected genes. It is envisioned that DNA encoding a gene
of interest may also be transferred in a similar manner in
vivo and express the gene product.
In still another embodimentof the invention for transfer-
ring a naked DNA expression construct into cells may
involve particle bombardment. This method depends on the
ability to accelerate DNA-coated microprojectiles to a high
velocity allowing them to pierce cell membranes and enter
cells without killing them (Klein et al., 1987). Several
devices for accelerating small particles have been devel-
oped. One such device relies on a high voltage discharge to
generate an electrical current, which in turn provides the
motive force (Yang et al., 1990). The microprojectiles used
have consisted of biologically inert substances such as
tungsten or gold beads.
Selected organs including the liver, skin, and muscle
tissue of rats and mice have been bombarded in vivo (Yang
et al., 1990; Zelenin et al., 1991). This may require surgical
exposure of the tissue or cells, to eliminate any intervening
tissue between the gun and the target organ, i.e., ex vivo
treatment. Again, DNA encoding a particular gene may be
delivered via this method and still be incorporated by the
present invention.
In a further embodimentof the invention, the expression
construct may be entrapped in a liposome. Liposomesare
vesicular structures characterized by a phospholipid bilayer
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membrane and an inner aqueous medium. Multilamellar
liposomes have multiple lipid layers separated by aqueous
medium. They form spontaneously when phospholipids are
suspended in an excess of aqueous solution. The lipid
components undergo self-rearrangement before the forma-
tion of closed structures and entrap water and dissolved
solutes between the lipid bilayers (Ghosh and Bachhawat,
1991). Also contemplated are lipofectamine-DNA com-
plexes.
Liposome-mediated nucleic acid delivery and expression
of foreign DNA in vitro has been very successful. Wong et
al., (1980) demonstrated the feasibility of liposome-medi-
ated delivery and expression of foreign DNA in cultured
chick embryo, HeLa and hepatomacells. Nicolau et al.,
(1987) accomplished successful liposome-mediated gene
transfer in rats after intravenous injection.
In certain embodiments of the invention, the liposome
may be complexed with a hemagglutinating virus (HVJ).
This has been shown to facilitate fusion with the cell
membrane and promotecell entry of liposome-encapsulated
DNA (Kaneda et al., 1989). In other embodiments, the
liposome may be complexed or employed in conjunction
with nuclear non-histone chromosomal proteins (HMG-1)
(Kato et al., 1991). In yet further embodiments, the liposome
may be complexed or employed in conjunction with both
HVJ and HMG-1. In that such expression constructs have
been successfully employed in transfer and expression of
nucleic acid in vitro and in vivo, then they are applicable for
the present invention. Where a bacterial promoter is
employed in the DNA construct, it also will be desirable to
include within the liposome an appropriate bacterial poly-
merase.
Other expression constructs which can be employed to
deliver a nucleic acid encoding a particular gene into cells
are receptor-mediated delivery vehicles. These take advan-
tage of the selective uptake of macromolecules by receptor-
mediated endocytosis in almost all eukaryotic cells. Because
of the cell type-specific distribution of various receptors, the
delivery can be highly specific (Wu and Wu, 1993).
Receptor-mediated gene targeting vehicles generally con-
sist of two components: a cell receptor-specific ligand and a
DNA-binding agent. Several ligands have been used for
receptor-mediated gene transfer. The most extensively char-
acterized ligands are asialoorosomucoid (ASOR) (Wu and
Wu, 1987) and transferrin (Wagneret al., 1990). Recently, a
synthetic neoglycoprotein, which recognizes the same
receptor as ASOR,has been used as a gene delivery vehicle
(Ferkol et al., 1993; Perales et al., 1994) and epidermal
growth factor (EGF) has also been used to deliver genes to
squamous carcinomacells (Myers, EPO 0273085).
In other embodiments, the delivery vehicle may comprise
a ligand and a liposome. For example, Nicolau et al. (1987)
employed lactosyl-ceramide, a galactose-terminal asialgan-
glioside, incorporated into liposomes and observed an
increase in the uptake of the insulin gene by hepatocytes.
Thus, it is feasible that a nucleic acid encoding a particular
gene also may be specifically delivered into a cell type by
any number of receptor-ligand systems with or without
liposomes. For example, epidermal growth factor (EGF)
may be used as the receptor for mediated delivery of a
nucleic acid into cells that exhibit upregulation of EGF
receptor. Mannose can be usedto target the mannose recep-
tor on liver cells. Also, antibodies to CD5 (CLL), CD22
(ymphoma), CD25 (T-cell leukemia) and MAA (melanoma)
can similarly be used as targeting moieties.
In a particular example, the oligonucleotide may be
administered in combination with a cationic lipid. Examples
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of cationic lipids include, but are not limited to, lipofectin,
DOTMA, DOPE, and DOTAP. The publication of
WO/0071096, which is specifically incorporated by refer-
ence, describes different formulations, such as a DOTAP:
cholesterol or cholesterol derivative formulation that can
effectively be used for gene therapy. Other disclosures also
discuss different lipid or liposomal formulations including
nanoparticles and methods of administration; these include,
butare not limited to, U.S. Patent Publication 20030203865,
20020150626, 20030032615, and 20040048787, which are
specifically incorporated by reference to the extent they
disclose formulations and other related aspects of adminis-
tration and delivery of nucleic acids. Methods used for
formingparticles are also disclosed in U.S. Pat. Nos. 5,844,
107, 5,877,302, 6,008,336, 6,077,835, 5,972,901, 6,200,801,
and 5,972,900, which are incorporated by reference for those
aspects.
In certain embodiments, gene transfer may more easily be
performed under ex vivo conditions. Ex vivo gene therapy
refers to the isolation of cells from an animal, the delivery
of a nucleic acid into the cells in vitro, and then the return
of the modified cells back into an animal. This may involve
the surgical removal of tissue/organs from an animal or the
primary culture of cells and tissues.
In some embodiments of the invention, it is desirable to
inhibit the expression or activity of miR-29a-c to increase
collagen deposition. For example, in one embodiment, the
invention provides a method ofinducing collagen deposition
in a tissue comprising contacting said tissue with an antago-
nist of miR-29a-c. The antagonist or inhibitor of miR-29a-c
function may be directed at miR-29a, miR-29b and/or at
miR-29¢c.
The function of miRNAs maybeinhibited by the admin-
istration of antagomirs. Initially described by Krfitzfeldt and
colleagues (Krfitzfeldt et al., 2005), “antagomirs”are single-
stranded, chemically-modified ribonucleotides that are at
least partially complementary to the miRNA sequence.
Antagomirs may comprise one or more modified nucleo-
tides, such as 2'-O-methyl-sugar modifications. In some
embodiments, antagomirs comprise only modified nucleo-
tides. Antagomirs may also comprise one or more phospho-
rothioate linkages resulting in a partial or full phosphoro-
thioate backbone.To facilitate in vivo delivery andstability,
the antagomir maybe linked to a cholesterol moiety at its 3'
end. Antagomirs suitable for inhibiting miRNAs may be
about 15 to about 50 nucleotides in length, more preferably
about 18 to about 30 nucleotides in length, and most
preferably about 20 to about 25 nucleotides in length.
“Partially complementary” refers to a sequence that is at
least about 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or
99% complementary to a target polynucleotide sequence.
The antagomirs maybeat least about 75%, 80%, 85%, 90%,
95%, 96%, 97%, 98%, or 99% complementary to a mature
miRNAsequence. In some embodiments, the antagomir may
be substantially complementary to a mature miRNA
sequence, that is at least about 95%, 96%, 97%, 98%, or
99% complementary to a target polynucleotide sequence. In
other embodiments, the antagomirs are 100% complemen-
tary to the mature miRNA sequence.
In one embodiment, the antagonist of miR-29a-c is an
antagomir. The antagomir may comprise a sequence that is
at least partially complementary to the mature miRNA
sequence of miR-29a, miR-29b, or miR-29c. In another
embodiment, the antagomir comprises a sequencethat is at
least partially complementary to the sequence of SEQ ID
NO: 18, SEQ ID NO: 19, or SEQ ID NO: 20. In another
US 9,719,088 B2
21
embodiment, the antagomir comprises a sequence that is
100% complementary to SEQ ID NO: 18, SEQ ID NO:19,
or SEQ ID NO: 20.
Inhibition ofmicroRNA function mayalso be achieved by
administering antisense oligonucleotides targeting the
mature miR-29a, miR-29b or miR-29c sequences. Theanti-
sense oligonucleotides may be ribonucleotides or deoxyri-
bonucleotides. Preferably, the antisense oligonucleotides
have at least one chemical modification. Antisense oligo-
nucleotides may be comprised of one or more “locked
nucleic acids”. “Locked nucleic acids” (LNAs) are modified
ribonucleotides that contain an extra bridge between the 2'
and 4' carbons of the ribose sugar moiety resulting in a
“locked” conformation that confers enhanced thermalsta-
bility to oligonucleotides containing the LNAs. Alterna-
tively, the antisense oligonucleotides may comprise peptide
nucleic acids (PNAs), which contain a peptide-based back-
bonerather than a sugar-phosphate backbone. Other chemi-
cal modifications that the antisense oligonucleotides may
contain include, but are not limited to, sugar modifications,
such as 2'-O-alkyl (e.g. 2'-O-methyl, 2'-O-methoxyethyl),
2'-fluoro, and 4' thio modifications, and backbone modifi-
cations, such as one or more phosphorothioate, morpholino,
or phosphonocarboxylate linkages (see, for example, U.S.
Pat. Nos. 6,693,187 and 7,067,641, which are herein incor-
porated by reference in their entireties). In some embodi-
ments, suitable antisense oligonucleotides are 2'-O-
methoxyethyl “gapmers” which contain 2'-O-methoxyethyl-
modified ribonucleotides on both 5' and 3' ends with at least
ten deoxyribonucleotides in the center. These “gapmers” are
capable of triggering RNase H-dependent degradation
mechanisms of RNA targets. Other modifications of anti-
sense oligonucleotides to enhance stability and improve
efficacy, such as those described in U.S. Pat. No. 6,838,283,
whichis herein incorporated by reference in its entirety, are
knownin the art and are suitable for use in the methods of
the invention. Preferable antisense oligonucleotides useful
for inhibiting the activity of microRNAs are about 19 to
about 25 nucleotides in length. Antisense oligonucleotides
may comprise a sequencethat is at least partially comple-
mentary to a mature miRNA sequence, e.g. at least about
75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%
complementary to a mature miRNA sequence. In some
embodiments, the antisense oligonucleotide may be substan-
tially complementary to a mature miRNA sequence, that is
at least about 95%, 96%, 97%, 98%, or 99% complementary
to a target polynucleotide sequence. In one embodiment, the
antisense oligonucleotide comprises a sequencethat is 100%
complementary to a mature miRNA sequence.
Tn another embodimentofthe invention, the antagonist of
miR-29a-c is a chemically-modified antisense oligonucle-
otide. The chemically-modified antisense oligonucleotide
may comprise a sequencethat is at least partially comple-
mentary to the mature miRNA sequence of miR-29a, miR-
29b, or miR-29c. In yet another embodiment, the chemi-
cally-modified antisense oligonucleotide comprises a
sequence that is at least partially complementary to the
sequence of SEQ ID NO: 18, SEQ ID NO: 19, or SEQ ID
NO: 20. In another embodiment, the chemically-modified
antisense oligonucleotide comprises a sequencethat is 100%
complementary to SEQ ID NO: 18, SEQ ID NO: 19, or SEQ
ID NO: 20.
Antisense oligonucleotides may comprise a sequence that
is substantially complementary to a precursor miRNA
sequence (pre-miRNA) for miR-29a-c. In some embodi-
ments, the antisense oligonucleotide comprises a sequence
that is substantially complementary to a sequence located
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outside the stem-loop region of the pre-miR-29a, pre-miR-
29b, or pre-miR-29¢ sequence.
Another approach for inhibiting the function of miR-
29a-c is administering an inhibitory RNA molecule having
at least partial sequence identity to the mature miR-29a,
miR-29b and miR-29¢ sequences. The inhibitory RNA mol-
ecule may be a double-stranded, small interfering RNA
(siRNA) or a short hairpin RNA molecule (shRNA) com-
prising a stem-loop structure. The double-stranded regions
of the inhibitory RNA molecule may comprise a sequence
thatis at least partially identical, e.g. about 75%, 80%, 85%,
90%, 95%, 96%, 97%, 98%, or 99% identical, to the mature
miRNA sequence. In some embodiments, the double-
strandedregionsofthe inhibitory RNA comprise a sequence
that is at least substantially identical to the mature miRNA
sequence. “Substantially identical” refers to a sequence that
is about 95%, 96%, 97%, 98%, or 99% identical to a target
polynucleotide sequence. In other embodiments, the double-
stranded regions of the inhibitory RNA molecule may be
100% identical to the target miRNA sequence.
In one embodiment, an antagonist of miR-29a-c is an
inhibitory RNA molecule comprising a double-stranded
region, wherein the double-stranded region comprises a
sequence having 100% identity to the mature miR-29a (SEQ
ID NO: 18), miR-29b (SEQ ID NO: 19), or miR-29¢ (SEQ
ID NO: 20) sequence. In some embodiments, antagonists of
miR-29a-c are inhibitory RNA molecules which comprise a
double-stranded region, wherein said double-stranded
region comprises a sequence of at least about 75%, 80%,
85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to the
mature miR-29a, miR-29b, or miR-29c sequence.
In another embodiment, an inhibitory RNAmolecule may
be a ribozyme. A ribozymeis a catalytic RNA that hydro-
lyzes phosphodiester bonds of RNA molecules. The
ribozyme maybe designedto target one or more ofmiR-29a,
miR-29b, and miR-29c resulting in their hydrolysis.
In certain embodiments, expression vectors are employed
to express an antagonist of miR-29a-c (e.g., antagomirs,
antisense oligonucleotides, and inhibitory RNA molecules).
In one embodiment, an expression vector for expressing an
antagonist of miR-29a-c comprises a promoter operably
linked to a polynucleotide encoding an antisense oligonucle-
otide, wherein the sequence of the expressed antisense
oligonucleotide is at least partially complementary to the
mature miR-29a, miR-29b, or miR-29c¢ sequence. In yet
another embodiment, an expression vector for expressing an
inhibitor of miR-29a-c comprises one or more promoters
operably linked to a polynucleotide encoding a shRNA or
siRNA, wherein the expressed shRNA or siRNA comprises
a sequence that is identical, partially identical, or substan-
tially identical to the mature miR-29a, miR-29b, or miR-29¢
sequence.“Partially identical” refers to a sequencethatis at
least about 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or
99% identical to a target polynucleotide sequence. “Sub-
stantially identical”refers to a sequencethatis at least about
95%, 96%, 97%, 98%, or 99% identical to a target poly-
nucleotide sequence.
Current medical management of cardiac hypertrophy in
the setting of a cardiovascular disorder includesthe use of at
least two types of drugs: inhibitors of the renin-angiotensin
system, and B-adrenergic blocking agents (Bristow, 1999).
Therapeutic agents to treat pathologic hypertrophy in the
setting of heart failure include angiotensin I] converting
enzyme (ACE) inhibitors and 6-adrenergic receptor block-
ing agents (Eichhorn and Bristow, 1996). Other pharmaceu-
tical agents that have been disclosed for treatment of cardiac
hypertrophy include angiotensin I] receptor antagonists
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(U.S. Pat. No. 5,604,251) and neuropeptide Y antagonists
(WO 98/33791). Despite currently available pharmaceutical
compounds, prevention and treatment of cardiac hypertro-
phy, and subsequent heart failure, continue to present a
therapeutic challenge.
Non-pharmacological treatment is primarily used as an
adjunct to pharmacological treatment. One means of non-
pharmacological treatment involves reducing the sodium in
the diet. In addition, non-pharmacological treatment also
entails the elimination of certain precipitating drugs, includ-
ing negative inotropic agents (e.g., certain calcium channel
blockers and antiarrhythmic drugs like diisopyramide), car-
diotoxins (e.g., amphetamines), and plasma volume expand-
ers (e.g., nonsteroidal anti-inflammatory agents and gluco-
corticoids).
The present invention provides a method of treating
cardiac fibrosis, cardiac hypertrophy or heart failure in a
subject in need thereof comprising identifying a subject
having cardiac fibrosis, cardiac hypertrophy or heart failure;
and administering to the subject an agonist of miR-29
expression or function. Preferably, administration of a miR-
29 agonist results in the improvement of one or more
symptoms of pathologic cardiac fibrosis, hypertrophy or
heart failure in the subject, or in the delay in the transition
from cardiac hypertrophy to heart failure. The one or more
improved symptoms may be increased exercise capacity,
increased cardiac ejection volume,decreased left ventricular
end diastolic pressure, decreased pulmonary capillary wedge
pressure, increased cardiac output, or cardiac index, lowered
pulmonary artery pressures, decreased left ventricular end
systolic and diastolic dimensions, decreased cardiacfibrosis,
decreased collagen deposition in cardiac muscle, decreased
left and right ventricular wall stress, decreased wall tension,
increased quality of life, and decreased disease related
morbidity or mortality. In addition, use of agonists of
miR-29a-c may prevent cardiac hypertrophy and its associ-
ated symptoms from arising either directly or indirectly.
In another embodiment, there is provided a method of
preventing pathologic hypertrophy or heart failure in a
subject in need thereof comprising identifying a subject at
risk of developing pathologic cardiac hypertrophy or heart
failure; and promoting the expression or activity of miR-
29a-c in cardiac cells of the subject. Cardiac cells include
cardiac myocytes, fibroblasts, smooth muscle cells, endothe-
lial cells, and any other cell type normally found in cardiac
tissue. The miR-29a-c agonist may be an agonist of miR-
29a, miR-29b and/or miR-29c. The subject at risk may
exhibit one or more of a list of risk factors comprising
cardiac fibrosis, low expression of miR-29, long-standing
uncontrolled hypertension, uncorrected valvular disease,
chronic angina, recent myocardial infarction, congenital
predisposition to heart disease and/or pathological hypertro-
phy, and/or may be diagnosed as having a genetic predis-
position to cardiac hypertrophy, and/or may have a familial
history of cardiac hypertrophy.
In another embodiment, there is provided a method of
treating myocardial infarction in a subject in need thereof
comprising promoting expression or activity of miR-29a-c
in cardiac cells of the subject. In another embodiment, the
invention provides a method of preventing cardiac hyper-
trophy and dilated cardiomyopathy in a subject in need
thereof comprising promoting expression or activity of
miR-29a-c in cardiac cells ofthe subject. In another embodi-
ment, the invention provides a method of inhibiting pro-
gression of cardiac hypertrophy in a subject in need thereof
comprising promoting expression or activity of miR-29a-c
in cardiac cells of the subject. Another embodiment is a
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method of increasing exercise tolerance in a subject with
heart failure or cardiac hypertrophy comprising promoting
expression or activity of miR-29a-c in cardiac cells of the
subject. Another embodiment is a method of reducing hos-
pitalization in a subject with heart failure or cardiac hyper-
trophy comprising promoting expression or activity ofmiR-
29a-c in cardiac cells of the subject. In some embodiments,
the invention provides methods for improving quality of life
and decreasing morbidity or mortality in a subject with heart
failure or cardiac hypertrophy comprising promoting
expression or activity of miR-29a-c in cardiac cells of the
subject.
Treatment regimens would vary dependingontheclinical
situation. However, long-term maintenance would appear to
be appropriate in most circumstances. It also may be desir-
able to treat hypertrophy with agonists of miR-29a-c inter-
mittently, such as within a brief window during disease
progression.
In addition, the miR-29 family is involved in the regula-
tion of cardiac fibrosis. Since this miR family is enriched in
fibroblasts compared to myocytes, it is likely that myocytes
secrete a factor, possibly BNP, which upregulates the miR-
29 family in fibroblast cells and thus protects against the
development of cardiac fibrosis. This factor is very high in
miR-208 KO mice, which correlates with the upregulation
of miR-29a-c and repression of fibrosis. miR-29a-c levels
are elevated in normal heart disease, which is likely a
protective effect to limit collagen deposition. Thus, the
particular use of miR-29a-c and agonists thereof in repress-
ing cardiac fibrosis and collagen deposition in cardiac tis-
sues is contemplated. A comparable mechanism for the
activation of the miR-29 family may be applicable in
skeletal muscle fibrosis as well. miR-29a-c regulates the
expression of a numberof extracellular matrix genes, such
as fibrillin 1 (FBN1), collagen type I, al (COL1AL), col-
lagen type I a2 (COL1A2), and collagen type IH, al
(COL3A1) (see Example 4). Accordingly, the present inven-
tion also provides methods of regulating one or more
extracellular matrix genes in a cell.
In one embodiment, the method comprises contacting the
cell with an agonist of miR-29 a-c. In another embodiment,
the method comprises contacting the cell with an antagonist
of miR-29a-c. In still another embodiment, the one or more
extracellular matrix genes includefibrillin 1 (FBN1), colla-
gen type I, al (COL1A1), collagen type I a2 (COL1A2),
and collagen type HI, a1 (COL3A1). In some embodiments,
the one or more extracellular matrix genes are upregulated
following contact of the cell with an antagonist of miR-29a-
c. In other embodiments, the one or more extracellular
matrix genes are downregulated following contactofthe cell
with an agonist of miR-29a-c.
The inventors have demonstrated that miR-29a-c expres-
sion was decreased in cardiac fibroblasts exposed to TGF6,
suggesting that the decrease in miR-29a-c following myo-
cardial infarction might be TGFB-regulated (Example 5).
Interestingly, natriuretic peptides like B-type natriuretic
peptide (BNP) have been shownto inhibit TGFB-regulated
gene expression related to fibrosis and myofibroblast con-
version (Kapounet al., 2004). In this regard, the inventors
reported previously that mice lacking the cardiac-specific
miRNA miR-208 were resistant to cardiac fibrosis and
remodeling and exhibited increased expression of BNP at
baseline (van Roojj et al., 2007). Since BNP is known to
antagonize the effects of TGF, the inventors suggest that
the increased levels of BNP in these mice might enhance the
expression of miR-29a-c. Indeed, a dose-dependent increase
in miR-29a-c expression was observed upon removal of
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miR-208, which coincided with an increasing expression
level of BNP (Example 5). These data indicate that TGFB
induces the expression of collagen related genes in fibro-
blasts at least partly through decreasing the level of miR-
29a-c, which can be inhibited by BNP secreted by cardio-
myocytes. Thus, the present invention provides a method of
increasing miR-29a-c expression and/or activity in a subject
by administering at least one TGF£ inhibitor. TGFinhibi-
tors may include anti-TGFB antibodies, TGFB antisense
molecules, and small molecules that inhibit TGFactivity as
described in U.S. Pat. No. 6,509,318, which is herein
incorporated by reference in its entirety. TGFB inhibitors
mayalso be used in conjunction with miR-29a-c agonists as
a combination therapy to treat cardiac fibrosis, cardiac
hypertrophy, or heart failure in a subject. TGF£ inhibitors
may also be co-administered with miR-29a-c agonists to
treat or prevent tissue fibrosis in a subject.
In addition to playing an important role in controlling
fibrosis in the heart, the ubiquitous expression of the miR-29
family suggests that it also mayplaya role in other fibrotic
indications, such as those involving the kidney, liver and
lungs. Fibrosis is also observed secondary to diabetes. Type
1 and type 2 diabetic patients are at increased risk of
cardiomyopathy. Cardiomyopathy in diabetes is associated
with a cluster of features, including decreased diastolic
compliance, interstitial fibrosis, and myocyte hypertrophy.
Thepresent invention also provides a methodoftreating
or preventing a tissue fibrosis in a subject. In one embodi-
ment, the method comprises identifying a subject having or
at risk oftissue fibrosis; and increasing the expression and/or
activity ofmiR-29a-c in skeletal muscleor fibroblast cells of
the subject. In another embodiment, the tissue fibrosis is
cardiac fibrosis, scleroderma (localized or systemic), skel-
etal muscle fibrosis, hepatic fibrosis, kidney fibrosis, pul-
monary fibrosis, or diabetic fibrosis. In some embodiments,
increasing the expression and/oractivity ofmiR-29a-c com-
prises administering an agonist of miR-29a-c to the subject.
In other embodiments, increasing the expression and/or
activity ofmiR-29a-c comprises administering to the subject
an expression vector that encodes miR-29a-c. In another
embodiment, the method further comprises administering to
the subject a non-miR-29a-c fibrotic therapy.
The present invention encompasses methods oftreating
tissue fibrosis associated with one or more conditions or
disorders in a subject in need thereof. In one embodiment,
the method comprises administering to the subject an ago-
nist of miR-29a-c. In another embodiment, the method
comprises administering to the subject an expression vector
that encodes miR-29a-c. The one or more conditions or
disorders associated with tissue fibrosis may include, but are
not limited to, congenital hepatic fibrosis (CHF); renal
tubulointerstitial fibrosis; pulmonary fibrosis associated with
an autoimmunedisorder(e.g. rheumatoid arthritis, lupus and
sarcoidosis); interstitial fibrosis associated with diabetic
cardiomyopathy; skeletal muscle fibrosis associated with
muscular dystrophies (e.g. Becker muscular dystrophy and
Duchenne muscular dystrophy), denervation atrophies, and
neuromuscular diseases (e.g. acute polyneuritis, poliomyeli-
tis, Werdig/Hoffman disease, amyotrophic lateral sclerosis,
and progressive bulbar atrophy disease).
Thepresent invention also contemplates methodsoftreat-
ing pathologies/deficiencies that are characterized by the
loss, lack, or underproduction of collagen. Using an antago-
nist of miR-29a-c, the expression of collagen can be
increasedto replace missing collagen or supplementexisting
collagen where there is a need. Thus, the present invention
provides a method of inducing collagen deposition in a
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tissue comprising contacting said tissue with an antagonist
of miR-29a-c. The antagonist may be directed at miR-29a,
miR-29b and/or at miR-29c. In one embodiment, the antago-
nist comprises a sequence that is complementary to SEQ ID
NO: 18. In another embodiment, the antagonist comprises a
sequence that is complementary to SEQ ID NO: 19. In
another embodiment, the antagonist comprises a sequence
that is complementary to SEQ ID NO: 20. The antagonist
may be an antagomir of miR-29a-c, an antisense oligonucle-
otide that targets a mature miR-29a-c sequence, or an
inhibitory RNAmolecule, such as a siRNA or a shRNA,that
comprises a sequence identical to a mature miR-29a-c
sequence, a ribozyme or any other inhibitory nucleic acid.
The antagonist may be linked or conjugated to agents that
facilitate the entry of the antagonist into cells or tissues.
Various conditions and disorders in which an increase in
collagen deposition would be beneficial and can be treated
by administering an antagonist ofmiR-29a-c include, but are
not limited to, Ehlers-Danlos syndrome (EDS); Vitamin C
deficiency (a.k.a scurvy); aging of the skin (e.g. natural
aging and photoaging due to sun damage); and stretch marks
(striae).
Ehlers-Danlos syndrome (EDS)is a group ofrare genetic
disorders affecting humans and domestic animals caused by
a defect in collagen synthesis. Depending on the individual
mutation, the severity of the disease can vary from mild to
life-threatening. Mutations in the ADAMTS2, COL1AI1,
COL1A2, COL3A1, COL5A1, COL5A2, PLOD1 and
TNXB genes cause EDS. Mutations in these genes usually
alter the structure, production, or processing of collagen or
proteins that interact with collagen. A defect in collagen can
weaken connective tissue in the skin, bones, blood vessels,
and organs, resulting in the features of the disorder. Thus,
collagen deposition induced by miR-29a-c antagonists ofthe
invention would act to replenish the level ofnormal collagen
in EDS patients and alleviate symptoms of the disease.
Similarly, administration of an antagonist of miR-29a-c
would benefit subjects suffering from vitamin C deficiency
or scurvy. Vitamin C deficiency is a disease that results from
insufficient intake ofvitamin C, which is required for normal
collagen synthesis in humans.
Collagen deposition in tissues resulting from the admin-
istration of an antagonist ofmiR-29a-c would also be useful
in various cosmetic applications. Effects of aging of the skin
produced by natural aging processes or photodamageresult-
ing from over-exposure to the sun could be reduced by
administering to a subject in need thereof a miR-29a-c
antagonist. Administration of miR-29a-c antagonists may
also facilitate the disappearance of stretch marks. Stretch
marks are a form of scarring on the skin that are caused by
tearing of the dermis. Stretch marks are the result of the
rapid stretching of the skin associated with rapid growth
(commonin puberty) or weight gain (e.g., pregnancy).
Thetissue to which the inventive methods maybe applied
include facial tissue, such a forehead tissue, a lip, a cheek,
a chin, an eyebrow, an eyelid, under the eye, or near the
mouth, hand tissue, neck tissue, arm tissue, leg tissue,
stomachtissue or breast tissue. In some embodiments, the
tissue may comprise a wound, a skin graft, scar tissue,
wrinkles, lax skin, sun damage, chemical damage, heat
damage, cold damage, and/or stretch marks.
In another embodimentofthe invention, the contacting of
the tissue with the miR-29a-c antagonist comprises injection
into said tissue, injection into vasculature that feeds said
tissue, or topical application. The topical application may be
an ointment, cream, gel, salve, or balm. In another embodi-
ment, the method further comprises use of a pressure ban-
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dage or dressing. The antagonist of miR-29a-c may be
contacted with said tissue more than once. In some embodi-
ments, the antagonist is contacted with said tissue 2, 3, 4, 5,
6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90
or 100 times. In other embodiments, the antagonist is
contacted with said tissue over 2, 3, 4, 5, or 6 days, 1, 2, 3,
or 4 weeks, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 months, or 1,
2, 3, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, or 25 years.
In still another embodiment, the method further comprises
contacting said tissue with a second agent. The second agent
may include, but is not limited to, topical vitamin A, topical
vitamin C, or vitamin E. In another embodiment, the method
further comprises subjecting said tissue to a secondtreat-
ment. The second treatment may comprise a chemical peel,
laser treatment, dermaplaning, or dermabrasion. In another
embodiment, the tissue is in a subject that suffers from
Ehler’s-Danlos syndrome or Vitamin C deficiency.
The present invention also contemplates the use of miR-
29a-c antagonists as profibrotic agents to convert soft
plaques in the vasculature into fibrotic tissue to prevent
myocardial infarction. Soft plaques are a build-up of lipids
containing predominantly cholesterol that lie underneath the
endothelial lining of the arterial wall. Recently, it was
recognized that these soft plaques are prone to rupture
resulting in the formation of a blood clot, which can poten-
tially block blood flow through the artery and cause a heart
attack (i.e. myocardial infarction). It is these soft plaques
that are often responsible in causing a healthy subject with
no symptomsto suffer a seemingly unexpected heart attack.
After a soft plaque ruptures, the vessel wall heals and the
soft plaque becomes a hard plaque, which rarely cause
further problems. Thus, strategies for converting soft
plaques into fibrotic tissue would prevent the soft plaques
from rupturing and possibly inducing a myocardial infarc-
tion.
As described in detail above, inhibition of miR-29a-c
leads to an increase in collagen deposition and the formation
of fibrotic tissue. Accordingly, the present invention pro-
vides a methodfor increasing fibrotic tissue formation in the
wall of a vessel comprising delivering an antagonist of
miR-29a-c to one or more soft plaquesites in the vessel wall,
wherein the soft plaque is converted to fibrotic tissue fol-
lowing delivery of the antagonist ofmiR-29a-c. Soft plaques
can be identified by methods knownin theart, including, but
not limited to, intravascular ultrasound and computed
tomography (Sahara et al. (2004) European Heart Journal,
Vol. 25: 2026-2033; Budhoff (2006) J. Am. Coll. Cardiol.,
Vol. 48: 319-321; Hausleiter et al. (2006) J. Am. Coll.
Cardiol., Vol. 48: 312-318). Any of the miR-29a-c antago-
nists described herein are suitable for use in the method.
The miR-29a-c antagonist may delivered to the one or
more soft plaque sites by direct injection or by using a
catheter or a device that isolates the coronary circulation. In
one embodiment, the miR-29a-c antagonist is delivered to
the one or more soft plaque sites by a medical device used
in vascular surgery, such as a stent or balloon. The miR-29
antagonist may be coated on a metal stent to form a
drug-eluting stent. A drug-eluting stent is a scaffold that
holds open narrowed or diseased arteries and releases a
compound to prevent cellular proliferation and/or inflam-
mation. miR-29a-c antagonists may be applied to a metal
stent imbedded in a thin polymer for release of the miR-
29a-c over time. Methods of coating stents with therapeutic
compounds are known in the art. See, e.g., U.S. Pat. No.
7,144,422; US. Pat. No. 7,055,237; and WO 2004/004602,
which are here incorporated by reference in their entireties.
In some embodiments, the miR-29a-c may be used in
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combination with other anti-restenosis compounds to pro-
duce a formulation for incorporation into drug-eluting stents
and balloons. Suitable compounds for use in combination
with the antagonists of miR-29a-c include, but are not
limited to, paclitaxel, rapamycin (sirolimus), tacrolimus,
zotarolimus, everolimus, docetaxel, pimecrolimus, and
derivatives thereof.
The present invention also contemplates methods for
scavenging or clearing a miR-29a-c agonist followingtreat-
ment. In one embodiment, the method comprises overex-
pression of binding site regions for miR-29a-c in fibroblasts
using a fibroblast specific promoter. The bindingsite regions
preferably contain a sequence of the seed region for miR-
29a-c. In some embodiments, the binding site may contain
a sequence from the 3'UTR of one or more targets of
miR-29a-c, such as COL1A1, COL1A2, COL1A3 and/or
FBN1. In another embodiment, a miR-29a-c antagonist may
be administered after a miR-29a-c agonist to attenuate or
stop the function of the microRNA.In another embodiment,
the present invention provides a method for scavenging or
clearing miR-29a-c antagonists following treatment. The
method may comprise overexpressing binding sites for the
miR-20a-c antagonists in fibroblasts or othertissue in which
a miR-29a-c antagonist was administered.
Combined Therapy
In another embodiment,it is envisioned to use an agonist
ofmiR-29a-c in combination with other therapeutic modali-
ties for treating cardiac hypertrophy, heart failure and myo-
cardial infarction. Thus, one may also provide to the subject
more “standard” pharmaceutical cardiac therapies in com-
bination with the miR-29a-c agonist. Examples of other
therapies include, without limitation, so-called “beta block-
ers,” anti-hypertensives, cardiotonics, anti-thrombotics,
vasodilators, hormone antagonists, iontropes, diuretics,
endothelin receptor antagonists, calcium channel blockers,
phosphodiesterase inhibitors, ACE inhibitors, angiotensin
type 2 antagonists and cytokine blockers/inhibitors, and
HDACinhibitors.
Combinations may be achieved by contacting cardiac
cells with a single composition or pharmacological formu-
lation that includes an agonist of miR-29a-c and a standard
pharmaceutical agent, or by contacting the cell with two
distinct compositions or formulations, at the same time,
wherein one composition includes an agonist of miR-29a-c
and the other includes the standard pharmaceutical agent.
Alternatively, the therapy using an agonist of miR-29a-c
may precede or follow administration of the other agent(s)
by intervals ranging from minutes to weeks. In embodiments
where the standard pharmaceutical agent and miR-29a-c
agonist are applied separately to the cell, one would gener-
ally ensure that a significant period of time did not expire
between the time of each delivery, such that the pharma-
ceutical agent and miR-29a-c agonist would still be able to
exert an advantageously combinedeffect on the cell. In such
instances,it is contemplated that one would typically contact
the cell with both modalities within about 12-24 hours of
each other and, more preferably, within about 6-12 hours of
each other, with a delay time of only about 12 hours being
most preferred. In some situations, it may be desirable to
extend the time period for treatment significantly, however,
where several days (2, 3, 4, 5, 6 or 7) to several weeks(1,
2, 3, 4, 5, 6, 7 or 8) lapse between the respective adminis-
trations.
It also is conceivable that more than one administration of
either an agonist of miR-29a-c, or the other pharmaceutical
agent will be desired. In this regard, various combinations
may be employed. By wayofillustration, where the agonist
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of miR-29a-c is “A”and the other agentis “B,” the follow-
ing permutations based on 3 and 4 total administrations are
exemplary:
A/B/A B/A/B B/B/A A/A/B B/A/A A/B/B BBB/A B/B/A/B
A/A/B/B_ A/B/A/B A/B/B/A B/B/A/A B/A/B/A B/A/A/B
BBB/A
A/A/A/B B/A/A/A A/B/A/A A/A/B/A A/B/B/B: B/A/B/B
B/B/A/B
Other combinations are likewise contemplated.
Pharmacological therapeutic agents and methods of
administration, dosages, etc., are well known to those of
skill in the art (see for example, the “Physicians Desk
Reference”, Klaassen’s “The Pharmacological Basis of
Therapeutics”, “Remington’s Pharmaceutical Sciences”,
and “The Merck Index, Eleventh Edition”, incorporated
herein by reference in relevant parts), and may be combined
with the invention in light of the disclosures herein. Some
variation in dosage will necessarily occur depending on the
condition of the subject being treated. The person respon-
sible for administration will, in any event, determine the
appropriate dose for the individual subject, and such indi-
vidual determinations are within the skill of those of ordi-
nary skill in the art.
Non-limiting examples of a pharmacological therapeutic
agent that may be used in the present invention include an
antihyperlipoproteinemic agent, an  antiarteriosclerotic
agent, an antithrombotic/fibrinolytic agent, a blood coagu-
lant, an antiarrhythmic agent, an antihypertensive agent, a
vasopressor, a treatment agent for congestive heart failure,
an antianginal agent, an antibacterial agent or a combination
thereof.
In addition, it should be noted that any of the following
may be used to develop new sets of cardiac therapy target
genes as B-blockers were used in the present examples (see
below). While it is expected that many of these genes may
overlap, new genetargets likely can be developed.
In certain embodiments, administration of an agent that
lowers the concentration of one of more blood lipids and/or
lipoproteins, known herein as an “antihyperlipoproteine-
mic,” may be combined with a cardiovascular therapy
according to the present invention, particularly in treatment
of atherosclerosis and thickenings or blockages of vascular
tissues. In certain embodiments, an antihyperlipoproteine-
mic agent may comprise an aryloxyalkanoic/fibric acid
derivative, a resin/bile acid sequesterant, a HMG CoA
reductase inhibitor, a nicotinic acid derivative, a thyroid
hormoneor thyroid hormone analog, a miscellaneous agent
or a combination thereof.
Non-limiting examples of aryloxyalkanoic/fibric acid
derivatives include beclobrate, enzafibrate, binifibrate, cip-
rofibrate, clinofibrate, clofibrate (atromide-S), clofibric acid,
etofibrate, fenofibrate, gemfibrozil (lobid), nicofibrate, piri-
fibrate, ronifibrate, simfibrate and theofibrate.
Non-limiting examples of resins/bile acid sequestrants
include cholestyramine (cholybar, questran), colestipol
(colestid) and polidexide.
Non-limiting examples of HMG CoA reductase inhibitors
include lovastatin (mevacor), pravastatin (pravochol) or
simvastatin (zocor).
Non-limiting examples of nicotinic acid derivatives
include nicotinate, acepimox, niceritrol, nicoclonate, nico-
mol and oxiniacic acid.
Non-limiting examples of thyroid hormones and analogs
thereof include etoroxate, thyropropic acid and thyroxine.
Non-limiting examples of miscellaneous antihyperlipo-
proteinemics include acifran, azacosterol, benfluorex,
B-benzalbutyramide, carnitine, chondroitin sulfate, clom-
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estrone, detaxtran, dextran sulfate sodium, 5,8,11,14,17-
eicosapentaenoic acid, eritadenine, furazabol, meglutol,
melinamide, mytatrienediol, ornithine, y-oryzanol, pan-
tethine, pentaerythritol tetraacetate, a-phenylbutyramide,
pirozadil, probucol (lorelco), B-sitosterol, sultosilic acid-
piperazine salt, tiadenol, triparanol and xenbucin. Non-
limiting examples of an antiarteriosclerotic include pyridi-
nol carbamate.
In certain embodiments, administration of an agent that
aids in the removal or prevention of blood clots may be
combined with administration of a modulator, particularly in
treatment of atherosclerosis and vasculature (e.g., arterial)
blockages. Non-limiting examples of antithrombotic and/or
fibrinolytic agents include anticoagulants, anticoagulant
antagonists, antiplatelet agents, thrombolytic agents, throm-
bolytic agent antagonists or combinations thereof.
In certain embodiments, antithrombotic agents that can be
administered orally, such as, for example, aspirin and
wafarin (coumadin), are preferred.
Non-limiting examples of anticoagulants include aceno-
coumarol, ancrod, anisindione, bromindione, clorindione,
coumetarol, cyclocumarol, dextran sulfate sodium, dicuma-
rol, diphenadione, ethyl biscoumacetate, ethylidene dicou-
marol, fluindione, heparin, hirudin, lyapolate sodium, oxaz-
idione, pentosan polysulfate, phenindione, phenprocoumon,
phosvitin, picotamide, tioclomarol and warfarin.
Non-limiting examples of antiplatelet agents include aspi-
rin, a dextran, dipyridamole (persantin), heparin, sulfinpyra-
none (anturane) and ticlopidine(ticlid).
Non-limiting examples of thrombolytic agents include
tissue plaminogen activator (activase), plasmin, pro-uroki-
nase, urokinase (abbokinase) streptokinase (streptase), anis-
treplase/APSAC (eminase).
In certain embodiments wherein a subject is suffering
from a hemorrhage or an increased likelihood of hemor-
rhaging, an agent that may enhance blood coagulation may
be used. Non-limiting examples of a blood coagulation
promoting agents include thrombolytic agent antagonists
and anticoagulant antagonists.
Non-limiting examples of anticoagulant antagonists
include protamine and vitamine K1.
Non-limiting examples of thrombolytic agent antagonists
include aminocaproic acid (amicar) and tranexamic acid
(amstat). Non-limiting examples of antithrombotics include
anagrelide, argatroban, cilstazol, daltroban, defibrotide,
enoxaparin, fraxiparine, indobufen, lamoparan, ozagrel,
picotamide, plafibride, tedelparin, ticlopidine andtriflusal.
Non-limiting examples of antiarrhythmic agents include
Class I antiarrhythmic agents (sodium channel blockers),
Class II antiarrhythmic agents (beta-adrenergic blockers),
Class III antiarrhythmic agents (repolarization prolonging
drugs), Class IV antiarrhythmic agents (calcium channel
blockers) and miscellaneous antiarrhythmic agents.
Non-limiting examples of sodium channel blockers
include Class IA, Class IB and Class IC antiarrhythmic
agents. Non-limiting examples of Class IA antiarrhythmic
agents include disppyramide (norpace), procainamide (pron-
estyl) and quinidine (quinidex). Non-limiting examples of
Class IB antiarrhythmic agents include lidocaine (xylo-
calne), tocamide (tonocard) and mexiletine (mexitil). Non-
limiting examples of Class IC antiarrhythmic agents include
encainide (enkaid) and flecainide (tambocor).
Non-limiting examples of a 6-blocker, otherwise known
as a B-adrenergic blocker, a f-adrenergic antagonist or a
Class II antiarrhythmic agent, include acebutolol (sectral),
alprenolol, amosulalol, arotinolol, atenolol, befunolol,
betaxolol, bevantolol, bisoprolol, bopindolol, bucumolol,
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bufetolol, bufuralol, bunitrolol, bupranolol, butidrine hydro-
chloride, butofilolol, carazolol, carteolol, carvedilol, celip-
rolol, cetamolol, cloranolol, dilevalol, epanolol, esmolol
(brevibloc), indenolol, labetalol, levobunolol, mepindolol,
metipranolol, metoprolol, moprolol, nadolol, nadoxolol,
nifenalol, nipradilol, oxprenolol, penbutolol, pindolol, prac-
tolol, pronethalol, propanolol (inderal), sotalol (betapace),
sulfinalol, talinolol, tertatolol, timolol, toliprolol and xib-
inolol. In certain embodiments, the beta blocker comprises
an  aryloxypropanolamine derivative. |Non-limiting
examples of aryloxypropanolaminederivatives include ace-
butolol, alprenolol, arotinolol, atenolol, betaxolol, bevan-
tolol, bisoprolol, bopindolol, bunitrolol, butofilolol, caraz-
olol, carteolol, carvedilol, celiprolol, cetamolol, epanolol,
indenolol, mepindolol, metipranolol, metoprolol, moprolol,
nadolol, nipradilol, oxprenolol, penbutolol, pindolol, propa-
nolol,talinolol,tertatolol, timolol and toliprolol.
Non-limiting examples of an agent that prolong repolar-
ization, also known as a Class III antiarrhythmic agent,
include amiodarone (cordarone) and sotalol (betapace).
Non-limiting examples of a calcium channel blocker,
otherwise knownas a Class IV antiarrhythmic agent, include
an arylalkylamine (e.g., bepridile, diltiazem, fendiline, gal-
lopamil, prenylamine, terodiline, verapamil), a dihydropyri-
dine derivative (felodipine, isradipine, nicardipine, nife-
dipine, nimodipine, nisoldipine, nitrendipine) a piperazinde
derivative (e.g., cinnarizine, flunarizine, lidoflazine) or a
micellaneous calctum channel blocker such as bencyclane,
etafenone, magnesium, mibefradil or perhexyline. In certain
embodiments a calcium channel blocker comprises a long-
acting dihydropyridine (nifedipine-type) calcium antagonist.
Non-limiting examples of miscellaneous antiarrhythmic
agents include adenosine (adenocard), digoxin (lanoxin),
acecamide, ajmaline, amoproxan, aprindine, bretylium tosy-
late, bunaftine, butobendine, capobenic acid, cifenline,
disopyranide, hydroquinidine, indecamide, ipatropium bro-
mide, lidocaine, lorajmine, lorcamide, meobentine, mori-
cizine, pirmenol, prajmaline, propafenone, pyrinoline, qui-
nidine polygalacturonate, quinidine sulfate and viquidil.
Non-limiting examples of antihypertensive agents include
sympatholytic, alpha/beta blockers, alpha blockers, anti-
angiotensin II agents, beta blockers, calcium channel block-
ers, vasodilators and miscellaneous antihypertensives.
Non-limiting examples of an a-blocker, also known as an
a-adrenergic blocker or an a-adrenergic antagonist, include
amosulalol, arotinolol, dapiprazole, doxazosin, ergoloid
mesylates, fenspiride, indoramin, labetalol, nicergoline, pra-
zosin, terazosin, tolazoline, trimazosin and yohimbine. In
certain embodiments, an alpha blocker may comprise a
quinazoline derivative. Non-limiting examples of quinazo-
line derivatives include alfuzosin, bunazosin, doxazosin,
prazosin, terazosin and trimazosin.
In certain embodiments, an antihypertensive agent is both
an a- and f-adrenergic antagonist. Non-limiting examples
of an alpha/beta blocker comprise labetalol (normodyne,
trandate).
Non-limiting examples of anti-angiotensin II agents
include angiotensin converting enzymeinhibitors and angio-
tensin II receptor antagonists. Non-limiting examples of
angiotensin converting enzyme inhibitors (ACE inhibitors)
include alacepril, enalapril (vasotec), captopril, cilazapril,
delapril, enalaprilat, fosinopril, lisinopril, moveltopril, per-
indopril, quinapril and ramipril. Non-limiting examples of
an angiotensin II receptor blocker, also known as an angio-
tensin I] receptor antagonist, an ANG receptor blocker or an
ANG-II type-1 receptor blocker (ARBS), include angiocan-
desartan, eprosartan, irbesartan, losartan and valsartan.
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Non-limiting examples of a sympatholytic include a cen-
trally acting sympatholytic or a peripherally acting sym-
patholytic. Non-limiting examples of a centrally acting
sympatholytic, also known as an central nervous system
(CNS) sympatholytic, include clonidine (catapres), gua-
nabenz (wytensin) guanfacine (tenex) and methyldopa(al-
domet). Non-limiting examples of a peripherally acting
sympatholytic include a ganglion blocking agent, an adren-
ergic neuron blocking agent, a B-adrenergic blocking agent
or a alphal-adrenergic blocking agent. Non-limiting
examples of a ganglion blocking agent include mecamylam-
ine (inversine) and trimethaphan (arfonad). Non-limiting
examples of an adrenergic neuron blocking agent include
guanethidine (ismelin) and reserpine (serpasil). Non-limit-
ing examples of a B-adrenergic blocker include acenitolol
(sectral), atenolol (tenormin), betaxolol (kerlone), carteolol
(cartrol), labetalol (normodyne, trandate), metoprolol (lo-
pressor), nadanol (corgard), penbutolol (levatol), pindolol
(visken), propranolol (inderal) and timolol (blocadren).
Non-limiting examples of alphal -adrenergic blocker include
prazosin (minipress), doxazocin (cardura) and terazosin
(hytrin).
In certain embodiments a cardiovasculator therapeutic
agent may comprise a vasodilator (e.g., a cerebral vasodi-
lator, a coronary vasodilator or a peripheral vasodilator). In
certain preferred embodiments, a vasodilator comprises a
coronary vasodilator. Non-limiting examples of a coronary
vasodilator include amotriphene, bendazol, benfurodil
hemisuccinate, benziodarone, chloracizine, chromonar,
clobenfurol, clonitrate, dilazep, dipyridamole, droprenil-
amine, efloxate, erythrityl tetranitrane, etafenone, fendiline,
floredil, ganglefene, herestrol bis(6-diethylaminoethyl
ether), hexobendine, itramin tosylate, khellin, lidoflanine,
mannitol hexanitrane, medibazine, nicorglycerin, pen-
taerythritol tetranitrate, pentrinitrol, perhexyline, pimethyl-
line, trapidil, tricromyl, trimetazidine, trolnitrate phosphate
and visnadine.
In certain embodiments, a vasodilator may comprise a
chronic therapy vasodilator or a hypertensive emergency
vasodilator. Non-limiting examples of a chronic therapy
vasodilator include hydralazine (apresoline) and minoxidil
(loniten). Non-limiting examples of a hypertensive emer-
gency vasodilator include nitroprusside (nipride), diazoxide
(hyperstat IV), hydralazine (apresoline), minoxidil (loniten)
and verapamil.
Non-limiting examples of miscellaneous antihyperten-
sives include ajmaline, y-aminobutyric acid, bufeniode,
cicletainine, ciclosidomine, a cryptenamine  tannate,
fenoldopam, flosequinan, ketanserin, mebutamate, mecam-
ylamine, methyldopa, methyl 4-pyridyl ketone thiosemicar-
bazone, muzolimine, pargyline, pempidine, pinacidil, pip-
eroxan, primaperone, a  protoveratrine, raubasine,
rescimetol, rilmenidene, saralasin, sodium nitrorusside, tic-
rynafen, trimethaphan camsylate, tyrosinase and urapidil.
In certain embodiments, an antihypertensive may com-
prise an arylethanolamine derivative, a benzothiadiazine
derivative, a N-carboxyalkyl(peptide/lactam) derivative, a
dihydropyridine derivative, a guanidine derivative, a hydra-
zines/phthalazine, an imidazole derivative, a quanternary
ammonium compound, a reserpine derivative or a sulfona-
mide derivative.
Non-limiting examples of arylethanolamine derivatives
include amosulalol, bufuralol, dilevalol, labetalol,
pronethalol, sotalol and sulfinalol.
Non-limiting examples of benzothiadiazine derivatives
include althizide, bendroflumethiazide, benzthiazide, ben-
zylhydrochlorothiazide, buthiazide, chlorothiazide, chlo-
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rthalidone, cyclopenthiazide, cyclothiazide, diazoxide, epi-
thiazide, ethiazide, fenquizone, hydrochlorothizide,
hydroflumethizide, methyclothiazide, meticrane, metola-
zone, paraflutizide, polythizide, tetrachlormethiazide and
trichlormethiazide.
Non-limiting examples of N-carboxyalkyl(peptide/
lactam) derivatives include alacepril, captopril, cilazapril,
delapril, enalapril, enalaprilat, fosinopril, lisinopril, mov-
eltipril, perindopril, quinapril and ramipril.
Non-limiting examples of dihydropyridine derivatives
include amlodipine, felodipine, isradipine, nicardipine, nife-
dipine, nilvadipine, nisoldipine and nitrendipine.
Non-limiting examples of guanidine derivatives include
bethanidine, debrisoquin, guanabenz, guanacline, guanadrel,
guanazodine, guanethidine, guanfacine, guanochlor, guan-
oxabenz and guanoxan.
Non-limiting examples of hydrazines/phthalazines
include budralazine, cadralazine, dihydralazine, endrala-
zine, hydracarbazine, hydralazine, pheniprazine, pildrala-
zine and todralazine.
Non-limiting examples of imidazole derivatives include
clonidine, lofexidine, phentolamine, tiamenidine and tolo-
nidine.
Non-limiting examples of quanternary ammonium com-
pounds include azamethonium bromide, chlorisondamine
chloride, hexamethonium, pentacynium bis(methylsulfate),
pentamethonium bromide, pentolinium tartrate, phenactro-
pinium chloride and trimethidinium methosulfate.
Non-limiting examples of reserpine derivatives include
bietaserpine, deserpidine, rescinnamine, reserpine and syro-
singopine.
Non-limiting examples of sulfonamide derivatives
include ambuside, clopamide, furosemide, indapamide,
quinethazone, tripamide and xipamide.
Vasopressors generally are used to increase blood pres-
sure during shock, which may occur during a surgical
procedure. Non-limiting examples of a vasopressor, also
known as an antihypotensive, include amezinium methyl
sulfate, angiotensin amide, dimetofrine, dopamine,
etifelmin, etilefrin, gepefrine, metaraminol, midodrine, nor-
epinephrine, pholedrine and synephrine.
Non-limiting examples of agents for the treatment of
congestive heart failure include anti-angiotensin I agents,
afterload-preload reduction treatment, diuretics and ino-
tropic agents.
In certain embodiments, an animal subject that can not
tolerate an angiotensin antagonist may be treated with a
combination therapy. Such therapy may combine adminis-
tration of hydralazine (apresoline) and isosorbide dinitrate
(isordil, sorbitrate).
Non-limiting examples of a diuretic include a thiazide or
benzothiadiazine derivative (e.g., althiazide, bendroflumet-
hazide, benzthiazide, benzylhydrochlorothiazide, buthiaz-
ide, chlorothiazide, chlorothiazide, chlorthalidone, cyclo-
penthiazide, epithiazide, ethiazide, ethiazide, fenquizone,
hydrochlorothiazide, hydroflumethiazide, methyclothiazide,
meticrane, metolazone, paraflutizide, polythizide, tetrachlo-
romethiazide, trichlormethiazide), an organomercurial (e.g.,
chlormerodrin, meralluride, mercamphamide, mercaptom-
erin sodium, mercumallylic acid, mercumatilin dodium,
mercurous chloride, mersalyl), a pteridine (e.g., furtherene,
triamterene), purines (e.g., acefylline, 7-morpholinomethyl-
theophylline, pamobrom, protheobromine, theobromine),
steroids including aldosterone antagonists (e.g., canrenone,
oleandrin, spironolactone), a sulfonamide derivative (e.g.,
acetazolamide, ambuside, azosemide, bumetanide, butazol-
amide, chloraminophenamide, clofenamide, clopamide, clo-
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rexolone, diphenylmethane-4,4'-disulfonamide,  disulf-
amide, ethoxzolamide, furosemide, indapamide, mefruside,
methazolamide, piretanide, quinethazone, torasemide,trip-
amide, xipamide), a uracil (e.g., aminometradine, ami-
sometradine), a potassium sparing antagonist (e.g.,
amiloride, triamterene) or a miscellaneous diuretic such as
aminozine, arbutin, chlorazanil, ethacrynic acid, etozolin,
hydracarbazine, isosorbide, mannitol, metochalcone,
muzolimine, perhexyline, ticrnafen and urea.
Non-limiting examples of a positive inotropic agent, also
known as a cardiotonic, include acefylline, an acetyldigi-
toxin, 2-amino-4-picoline, aminone, benfurodil hemi succi-
nate, bucladesine, cerberosine, camphotamide, convalla-
toxin, cymarin, denopamine,deslanoside, digitalin, digitalis,
digitoxin, digoxin, dobutamine, dopamine, dopexamine,
enoximone, erythrophleine, fenalcomine, gitalin, gitoxin,
glycocyamine, heptaminol, hydrastinine, ibopamine, a lana-
toside, metamivam, milrinone, nerifolin, oleandrin, ouabain,
oxyfedrine, prenalterol, proscillaridine, resibufogenin, scil-
laren, scillarenin, strphanthin, sulmazole, theobromine and
xamoterol.
In particular embodiments, an intropic agent is a cardiac
glycoside, a beta-adrenergic agonist or a phosphodiesterase
inhibitor. Non-limiting examples of a cardiac glycoside
includes digoxin (lanoxin) and digitoxin (crystodigin). Non-
limiting examples of a f-adrenergic agonist include
albuterol, bambuterol, bitolterol, carbuterol, clenbuterol,
clorprenaline, denopamine, dioxethedrine, dobutamine
(dobutrex), dopamine (intropin), dopexamine, ephedrine,
etafedrine, ethylnorepinephrine, fenoterol, formoterol,
hexoprenaline, ibopamine, isoetharine, isoproterenol,
mabuterol, metaproterenol, methoxyphenamine, oxyfedrine,
pirbuterol, procaterol, protokylol, reproterol, rimiterol, rito-
drine, soterenol, terbutaline, tretoquinol, tulobuterol and
xamoterol. Non-limiting examples of a phosphodiesterase
inhibitor include aminone (inocor).
Antianginal agents may comprise organonitrates, calctum
channel blockers, beta blockers and combinations thereof.
Non-limiting examples of organonitrates, also known as
nitrovasodilators, include nitroglycerin (nitro-bid,nitrostat),
isosorbide dinitrate (isordil, sorbitrate) and amyl nitrate
(aspirol, vaporole).
Endothelin (ET) is a 21-aminoacid peptide that has potent
physiologic and pathophysiologic effects that appear to be
involved in the developmentof heart failure. The effects of
ETare mediated through interaction with twoclasses ofcell
surface receptors. The type A receptor (ET-A) is associated
with vasoconstriction and cell growth while the type B
receptor (ET-B)is associated with endothelial-cell mediated
vasodilation and with the release of other neurohormones,
such as aldosterone. Pharmacologic agents that can inhibit
either the production ofET orits ability to stimulate relevant
cells are known in the art. Inhibiting the production of ET
involves the use of agents that block an enzyme termed
endothelin-converting enzyme that is involved in the pro-
cessing of the active peptide from its precursor. Inhibiting
the ability of ET to stimulate cells involves the use of agents
that block the interaction of ET with its receptors. Non-
limiting examples of endothelin receptor antagonists (ERA)
include Bosentan, Enrasentan, Ambrisentan, Darusentan,
Tezosentan, Atrasentan, Avosentan, Clazosentan, Edonen-
tan, sitaxsentan, TBC 3711, BQ 123, and BQ 788.
In certain embodiments, the secondary therapeutic agent
may comprise a surgery of some type, which includes, for
example, preventative, diagnostic or staging, curative and
palliative surgery. Surgery, and in particular a curative
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surgery, may be used in conjunction with other therapies,
such as the present invention and one or more other agents.
Such surgical therapeutic agents for vascular and cardio-
vascular diseases and disorders are well known to those of
skill in the art, and may comprise, but are not limited to,
performing surgery on an organism, providing a cardiovas-
cular mechanical prostheses, angioplasty, coronary artery
reperfusion, catheter ablation, providing an implantable car-
dioverter defibrillator to the subject, mechanical circulatory
support or a combination thereof. Non-limiting examples of
a mechanical circulatory support that may be used in the
present invention comprise an intra-aortic balloon counter-
pulsation, left ventricular assist device or combination
thereof.
Drug Formulations and Routes for Administration to Sub-
jects
The present invention also provides a pharmaceutical
composition comprising an agonist or antagonist of miR-
29a-c. The agonist may be an expression vector comprising
a nucleic acid segment encoding miR-29a-c, or a polynucle-
otide comprising a mature miR-29a-c sequence or an effec-
tive portion thereof. The agonist may be comprised in alipid
delivery vehicle. The antagonist may be a polynucleotide
that hybridizes to miR-29a-c or a target thereof.
Where clinical applications are contemplated, pharma-
ceutical compositions will be prepared in a form appropriate
for the intended application. Generally, this will entail
preparing compositionsthat are essentially free of pyrogens,
as well as other impurities that could be harmful to humans
or animals.
Colloidal dispersion systems, such as macromolecule
complexes, nanocapsules, microspheres, beads, and lipid-
based systems including oil-in-water emulsions, micelles,
mixed micelles, and liposomes, may be used as delivery
vehicles for the oligonucleotide inhibitors (e.g. antagonists)
of microRNA function or constructs expressing particular
microRNAs. Commercially available fat emulsions that are
suitable for delivering the nucleic acids of the invention to
cardiac and skeletal muscle tissues include Intralipid®,
Liposyn®, Liposyn® IJ, Liposyn® II, Nutrilipid, and other
similarlipid emulsions. A preferred colloidal system for use
as a delivery vehicle in vivo is a liposome(1.e., an artificial
membranevesicle). The preparation and use of such systems
is well known in the art. Exemplary formulations are also
disclosed in U.S. Pat. Nos. 5,981,505; 6,217,900; 6,383,512;
5,783,565; 7,202,227; 6,379,965; 6,127,170; 5,837,533;
6,747,014; and WO03/093449, which are herein incorpo-
rated by reference in their entireties.
One will generally desire to employ appropriate salts and
buffers to render delivery vehicles stable and allow for
uptake by target cells. Buffers also will be employed when
recombinant cells are introduced into a subject. Aqueous
compositions of the present invention comprise an effective
amount of the delivery vehicle comprising the inhibitor
polynucleotides or miRNA polynucleotide sequences (e.g.
liposomes or other complexes or expression vectors) or
cells, dissolved or dispersed in a pharmaceutically accept-
able carrier or aqueous medium. The phrases “pharmaceu-
tically acceptable”or “pharmacologically acceptable”refers
to molecular entities and compositions that do not produce
adverse, allergic, or other untoward reactions when admin-
istered to an animal or a human.As used herein, “pharma-
ceutically acceptable carrier” includes solvents, buffers,
solutions, dispersion media, coatings, antibacterial and anti-
fungal agents, isotonic and absorption delaying agents and
the like acceptable for use in formulating pharmaceuticals,
such as pharmaceuticals suitable for administration to
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humans. The use of such media and agents for pharmaceu-
tically active substances is well knownin the art. Except
insofar as any conventional media or agent is incompatible
with the active ingredients of the present invention, its use
in therapeutic compositions is contemplated. Supplementary
active ingredients also can be incorporated into the compo-
sitions, provided they do not inactivate the vectors or cells
of the compositions.
The active compositions of the present invention may
include classic pharmaceutical preparations. Administration
of these compositions according to the present invention
may be via any commonroute so long as the target tissue is
available via that route. This includesoral, nasal, or buccal.
Alternatively, administration may be by intradermal, subcu-
taneous, intramuscular, intraperitoneal or intravenousinjec-
tion, or by direct injection into cardiac tissue. Pharmaceu-
tical compositions comprising miRNA antagonists or
expression constructs comprising miRNA sequences may
also be administered by catheter systems or systems that
isolate coronary circulation for delivering therapeutic agents
to the heart. Various catheter systems for delivering thera-
peutic agents to the heart and coronary vasculature are
known in the art. Some non-limiting examples of catheter-
based delivery methods or coronary isolation methodssuit-
able for use in the present invention are disclosed in U.S.
Pat. Nos. 6,416,510; 6,716,196; 6,953,466, WO 2005/
082440, WO 2006/089340, U.S. Patent Publication No.
2007/0203445, U.S. Patent Publication No. 2006/0148742,
and U.S. Patent Publication No. 2007/0060907, which are
all herein incorporated by reference in their entireties. Such
compositions would normally be administered as pharma-
ceutically acceptable compositions, as described supra.
The active compounds may also be administered paren-
terally or intraperitoneally. By way of illustration, solutions
of the active compoundsas free base or pharmacologically
acceptable salts can be prepared in water suitably mixed
with a surfactant, such as hydroxypropylcellulose. Disper-
sions can also be prepared in glycerol, liquid polyethylene
glycols, and mixtures thereof and in oils. Under ordinary
conditions of storage and use, these preparations generally
contain a preservative to prevent the growth of microorgan-
isms.
The pharmaceutical forms suitable for injectable use or
catheter delivery include, for example, sterile aqueous solu-
tions or dispersions and sterile powders for the extempora-
neous preparation of sterile injectable solutions or disper-
sions. Generally, these preparations are sterile and fluid to
the extent that easy injectability exists. Preparations should
be stable under the conditions of manufacture and storage
and should be preserved against the contaminating action of
microorganisms, such as bacteria and fungi. Appropriate
solvents or dispersion media may contain, for example,
water, ethanol, polyol (for example, glycerol, propylene
glycol, and liquid polyethylene glycol, and the like), suitable
mixtures thereof, and vegetable oils. The properfluidity can
be maintained, for example, by the use of a coating, such as
lecithin, by the maintenance of the required particle size in
the case of dispersion and by the use of surfactants. The
prevention of the action of microorganisms can be brought
about by various antibacterial an antifungal agents, for
example, parabens, chlorobutanol, phenol, sorbic acid,
thimerosal, and the like. In manycases, it will be preferable
to include isotonic agents, for example, sugars or sodium
chloride. Prolonged absorption of the injectable composi-
tions can be brought about by the use in the compositions of
agents delaying absorption, for example, aluminum monos-
tearate and gelatin.
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Sterile injectable solutions may be prepared by incorpo-
rating the active compounds in an appropriate amount into
a solvent along with any other ingredients (for example as
enumerated above) as desired, followed byfiltered steriliza-
tion. Generally, dispersions are prepared by incorporating
the varioussterilized active ingredients into a sterile vehicle
which containsthe basic dispersion medium andthe desired
other ingredients, e.g., as enumerated above.In the case of
sterile powders for the preparation of sterile injectable
solutions, the preferred methods of preparation include
vacuum-drying and freeze-drying techniques which yield a
powder of the active ingredient(s) plus any additional
desired ingredient from a previously sterile-filtered solution
thereof.
The compositions of the present invention generally may
be formulated in a neutral or salt form. Pharmaceutically-
acceptable salts include, for example, acid addition salts
(formed with the free amino groups of the protein) derived
from inorganic acids (e.g., hydrochloric or phosphoric acids,
or from organic acids (e.g., acetic, oxalic, tartaric, mandelic,
and the like. Salts formed with the free carboxyl groups of
the protein can also be derived from inorganic bases(e.g.,
sodium, potassium, ammonium,calcium, or ferric hydrox-
ides) or from organic bases (e.g., isopropylamine, trimeth-
ylamine, histidine, procaine andthelike.
Upon formulation, solutions are preferably administered
in a manner compatible with the dosage formulation and in
such amountasis therapeutically effective. The formulations
mayeasily be administeredin a variety ofdosage forms such
as injectable solutions, drug release capsules and the like.
For parenteral administration in an aqueous solution, for
example, the solution generally is suitably buffered and the
liquid diluent first rendered isotonic for example with suf-
ficient saline or glucose. Such aqueous solutions may be
used, for example, for intravenous, intramuscular, subcuta-
neous andintraperitoneal administration. Preferably, sterile
aqueous media are employedas is knownto those of skill in
the art, particularly in light of the present disclosure. By way
of illustration, a single dose may be dissolved in 1 ml of
isotonic NaCl solution and either added to 1000 ml of
hypodermoclysis fluid or injected at the proposed site of
infusion, (see for example, “Remington’s Pharmaceutical
Sciences” 15th Edition, pages 1035-1038 and 1570-1580).
Somevariation in dosage will necessarily occur depending
on the condition of the subject being treated. The person
responsible for administration will, in any event, determine
the appropriate dose for the individual subject. Moreover,
for human administration, preparations should meetsterility,
pyrogenicity, general safety and purity standards as required
by FDA Office of Biologics standards.
Cosmetic formulations for increasing collagen deposition
in tissues may comprise at least one antagonist of miR-29a-
c. The antagonist may be an antagonist of miR-29a, miR-
29b, miR-29c, or combinations thereof. In some embodi-
ments, the antagonist of miR-29a-c is an antagomir. The
antagonist may be linked or conjugated to agents that
facilitate the entry of the antagonistinto cell or tissues. Such
agents may include cell internalization transporters, such as
antennapedia, TAT, Buforin II, Transportan, model amphip-
athic peptide, K-FGF, Ku70, Prion, pVEC, Pep-1, SynB1,
SynB3, SynB5, Pep-7, HN-1, Bis-Guanidinitum-Spermi-
dine-Cholesterol, Bis-Guanidinium-Tren-Cholesterol, and
polyarginine. The agent may be linked to the miR-29a-c
antagonist at its amino or carboxy terminus. In one embodi-
ment, the agent is linked to the antagonist by a sequence that
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is cleaved upon entry to the cell. Such sequences typically
comprise consensus sequencesfor proteases as are known in
the art.
The cosmetic compositions can be formulated into all
types of vehicles. Non-limiting examples of suitable
vehicles include emulsions(e.g., water-in-oil, water-in-oil-
in-water, oil-in-water, oil-in-water-in-oil, oil-in-water-in-
silicone emulsions), creams, lotions, solutions (both aqueous
and hydro-alcoholic), anhydrous bases (such as lipsticks and
powders), gels, and ointments or by other method or any
combination of the forgoing as would be known to one of
ordinary skill in the art (Remington’s, 1990). Variations and
other appropriate vehicles will be apparent to the skilled
artisan and are appropriate for use in the present invention.
In certain embodiments, the concentrations and combina-
tions of the ingredients are selected in such a way that the
combinations are chemically compatible and do not form
complexes which precipitate from the finished product.
It is also contemplated that aromatic skin-active ingredi-
ents and additional ingredients identified throughout this
specification can be encapsulated for delivery to a target area
such as skin. Non-limiting examples of encapsulation tech-
niques include the use of liposomes, vesicles, and/or nano-
particles (e.g., biodegradable and non-biodegradable colloi-
dal particles comprising polymeric materials in which the
ingredient is trapped, encapsulated, and/or absorbed—ex-
amples include nanospheres and nanocapsules) that can be
used as delivery vehicles to deliver such ingredients to skin
(see, e.g., U.S. Pat. Nos. 6,387,398; 6,203,802; 5,411,744;
and Kreuter 1998, which are herein incorporated by refer-
ence in their entireties).
Also contemplated are pharmaceutically-acceptable or
pharmacologically-acceptable compositions. The phrase
“pharmaceutically-acceptable” or “pharmacologically-ac-
ceptable” includes compositions that do not produce an
allergic or similar untoward reaction when administered to
ahuman. Typically, such compositions are preparedeither as
topical compositions, liquid solutions or suspensions, solid
formssuitable for solution in, or suspension in, liquid prior
to use can also be prepared. Routes of administration can
vary with the location and nature of the condition to be
treated, and include, e.g., topical, inhalation, intradermal,
transdermal, parenteral, intravenous, intramuscular, intrana-
sal, subcutaneous, percutaneous, intratracheal, intraperito-
neal, intratumoral, perfusion, lavage, direct injection, and
oral administration and formulation.
The compositions of the present invention can be incor-
porated into products. Non-limiting examples of products
include cosmetic products, food-based products, pharma-
ceutical products, etc. By way ofexample only, non-limiting
cosmetic products include sunscreen products, sunless skin
tanning products, hair products, fingernail products, mois-
turizing creams, skin benefit creams and lotions, softeners,
day lotions, gels, ointments, foundations, night creams,
lipsticks, mascaras, eyeshadows, eyeliners, cheek colors,
cleansers, toners, masks, or other known cosmetic products
or applications. Additionally, the cosmetic products can be
formulated as leave-on or rinse-off products.
Compositions of the present invention can include addi-
tional ingredients. Non-limiting examples of additional
ingredients include cosmetic ingredients (both active and
non-active) and pharmaceutical ingredients (both active and
non-active). The CTFA International Cosmetic Ingredient
Dictionary and Handbook (2004) describes a wide variety of
non-limiting cosmetic ingredients that can be used in the
context of the present invention. Examples of these ingre-
dient classes include: fragrances (artificial and natural), dyes
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and color ingredients (e.g., Blue 1, Blue 1 Lake, Red 40,
titanium dioxide, D&C blue no. 4, D&C green no. 5, D&C
orange no. 4, D&C red no. 17, D&C red no. 33, D&C violet
no. 2, D&C yellow no. 10, and D&C yellow no. 11),
adsorbents, emulsifiers, stabilizers, lubricants, solvents,
moisturizers (including, e.g., emollients, humectants, film
formers, occlusive agents, and agents that affect the natural
moisturization mechanisms of the skin), water-repellants,
UV absorbers (physical and chemical absorbers such as
paraminobenzoic acid (“PABA”) and corresponding PABA
derivatives, titantum dioxide, zinc oxide, etc.), essential oils,
vitamins (e.g., A, B, C, D, E, and K), trace metals (e.g., zine,
calcium and selenium), anti-irritants (e.g., steroids and non-
steroidal anti-inflammatories), botanical extracts (e.g., aloe
vera, chamomile, cucumberextract, ginkgo biloba, ginseng,
and rosemary), anti-microbial agents, antioxidants (e.g.,
BHT and tocopherol), chelating agents (e.g., disodium
EDTAandtetrasodium EDTA), preservatives (e.g., methyl-
paraben and propylparaben), pH adjusters (e.g., sodium
hydroxide andcitric acid), absorbents (e.g., aluminum starch
octenylsuccinate, kaolin, corn starch, oat starch, cyclodex-
trin, talc, and zeolite), skin bleaching andlightening agents
(e.g., hydroquinone and niacinamide lactate), humectants
(e.g., glycerin, propylene glycol, butylene glycol, pentylene
glycol, sorbitol, urea, and manitol), exfoliants (e.g., alpha-
hydroxyacids, and beta-hydroxyacids such as lactic acid,
glycolic acid, and salicylic acid; and salts thereof) water-
proofing agents (e.g., magnesium/aluminum hydroxide
stearate), skin conditioning agents (e.g., aloe extracts, allan-
toin, bisabolol, ceramides, dimethicone, hyaluronic acid,
and dipotassium glycyrrhizate), thickening agents (e.g., sub-
stances which that can increase the viscosity of a composi-
tion such as carboxylic acid polymers, crosslinked polyacry-
late polymers, polyacrylamide polymers, polysaccharides,
and gums), and silicone containing compounds(e.g., sili-
cone oils and polyorganosiloxanes).
Pharmaceutical ingredients are also contemplated as
being useful with the emulsion compositions of the present
invention. Non-limiting examples of pharmaceutical ingre-
dients include anti-acne agents, agents usedto treat rosacea,
analgesics, anesthetics, anorectals, antihistamines, anti-in-
flammatory agents including non-steroidal anti-inflamma-
tory drugs, antibiotics, antifungals, antivirals, antimicrobi-
als, anti-cancer actives, scabicides, pediculicides,
antineoplastics, antiperspirants, antipruritics, antipsoriatic
agents, antiseborrheic agents, biologically active proteins
and peptides, burn treatment agents, cauterizing agents,
depigmenting agents, depilatories, diaper rash treatment
agents, enzymes, hair growth stimulants, hair growth retar-
dants including DFMOandits salts and analogs, hemostat-
ics, kerotolytics, canker sore treatment agents, cold sore
treatment agents, dental and periodontal treatment agents,
photosensitizing actives, skin protectant/barrier agents, ste-
roids including hormonesandcorticosteroids, sunburn treat-
ment agents, sunscreens, transdermal actives, nasal actives,
vaginal actives, wart treatment agents, wound treatment
agents, wound healing agents,etc.
Any of the compositions described herein may be com-
prised in a kit. In a non-limiting example, an individual
miRNA is included in a kit. The kit may further include
water and hybridization buffer to facilitate hybridization of
the two strands of the miRNAs. In some embodiments, the
kit may include one or more oligonucleotides for inhibiting
the function of a target miRNA. The kit may also include
one or more transfection reagent(s) to facilitate delivery of
the miRNA or miRNAantagonists to cells.
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The components of the kits may be packaged either in
aqueous media or in lyophilized form. The container means
of the kits will generally include at least one vial, test tube,
flask, bottle, syringe or other container means, into which a
component may be placed, and preferably, suitably ali-
quoted. Where there is more than one componentin the kit
(labeling reagent and label may be packaged together), the
kit also will generally contain a second, third or other
additional container into which the additional components
may be separately placed. However, various combinations
of components may be comprised in a vial. The kits of the
present invention also will typically include a means for
containing the nucleic acids, and any other reagent contain-
ers in close confinement for commercial sale. Such contain-
ers may include injection or blow-moldedplastic containers
into which the desired vials are retained.
When the components of the kit are provided in one
and/or more liquid solutions, the liquid solution is an aque-
ous solution, with a sterile aqueous solution being particu-
larly preferred.
However, the components of the kit may be provided as
dried powder(s). When reagents and/or components are
provided as a dry powder, the powder can be reconstituted
by the addition of a suitable solvent. It is envisioned that the
solvent may also be provided in another container means.
The container means will generally include at least one
vial, test tube, flask, bottle, syringe and/or other container
means, into which the nucleic acid formulations are placed,
preferably, suitably allocated. The kits may also comprise a
second container meansfor containing a sterile, pharmaceu-
tically acceptable buffer and/or other diluent.
The kits of the present invention will also typically
include a means for containing the vials in close confine-
ment for commercial sale, such as, e.g., injection and/or
blow-moldedplastic containers into which the desired vials
are retained.
Such kits may also include components that preserve or
maintain the miRNA or miRNAinhibitory oligonucleotides
or that protect against their degradation. Such components
may be RNAse-free or protect against RNAses. Such kits
generally will comprise, in suitable means, distinct contain-
ers for each individual reagent or solution.
A kit will also include instructions for employing the kit
components as well the use of any other reagent not included
in the kit. Instructions may include variations that can be
implemented. A kit may also include utensils or devices for
administering the miRNA agonist or antagonist by various
administration routes, such as parenteral or catheter admin-
istration.
It is contemplated that such reagents are embodiments of
kits of the invention. Such kits, however, are not limited to
the particular items identified above and may include any
reagent used for the manipulation or characterization of
miRNA.
Methods for Identifying Modulators
The present invention further comprises methods for
identifying agonists of miR-29a-c that are useful in the
prevention or treatment or reversal of cardiac fibrosis, car-
diac hypertrophy or heart failure. These assays may com-
prise random screening of large libraries of candidate com-
pounds; alternatively, the assays may be used to focus on
particular classes of compounds selected with an eye
towards structural attributes that are believed to make them
more likely to promote the expression and/or function of
miR-29a-c.
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To identify a modulator of miR-29a-c, one generally will
determine the function of a miR-29a-c in the presence and
absenceofthe candidate compound. For example, a method
generally comprises:
(a) providing a candidate compound;
(b) admixing the candidate compound with a miR-29;
(c) measuring miR-29a-c activity; and
(d) comparing the activity in step (c) with the activity of
miR-29a-c in the absence of the candidate compound,
wherein a difference between the measured activities of
miR-29a-c indicates that the candidate compoundis, indeed,
a modulator of miR-29a-c.
Assays also may be conductedin isolated cells, organs, or in
living organisms.
Tt will, of course, be understood that all the screening
methods of the present invention are useful in themselves
notwithstandingthe fact that effective candidates may not be
found. The invention provides methods for screening for
such candidates, not solely methods of finding them.
As used herein the term “candidate compound”refers to
any molecule that may potentially modulate fibrosis- or
collagen-regulating aspects ofmiR-29a-c. One will typically
acquire, from various commercial sources, molecular librar-
ies that are believed to meet the basic criteria for useful
drugs in an effort to “brute force”the identification of useful
compounds. Screening of such libraries, including combi-
natorially-generated libraries (e.g., antagomir libraries), is a
rapid and efficient way to screen a large numberofrelated
(and unrelated) compounds for activity. Combinatorial
approachesalso lend themselvesto rapid evolution of poten-
tial drugs by the creation of second, third, and fourth
generation compounds modeled on active, but otherwise
undesirable compounds.
A quick, inexpensive and easy assay to run is an in vitro
assay. Such assays generally use isolated molecules, can be
run quickly and in large numbers, thereby increasing the
amount of information obtainable in a short period of time.
A variety ofvessels may be usedto run the assays, including
test tubes, plates, dishes and other surfaces such as dipsticks
or beads.
A technique for high throughput screening of compounds
is described in WO 84/03564, which is herein incorporated
by reference in its entirety. Large numbers of small antago-
mir compounds may be synthesized on a solid substrate,
such as plastic pins or some other surface. Such molecules
can be rapidly screening for their ability to inhibit
miR-29a-c.
The present invention also contemplates the screening of
compounds for their ability to modulate miR-29a-c activity
and expression in cells. Various cell lines, including those
derived from skeletal muscle cells, can be utilized for such
screening assays, including cells specifically engineered for
this purpose. Primary cardiac cells also may be used, as can
the H9C2cell line.
In vivo assays involve the use of various animal models
of heart disease, musculoskeletal disease, fibrosis, or colla-
gen-loss including transgenic animals, that have been engi-
neered to have specific defects, or carry markers that can be
used to measure the ability of a candidate substance to reach
and affect different cells within the organism. Due to their
size, ease of handling, and information on their physiology
and genetic make-up, mice are a preferred embodiment,
especially for transgenics. However, other animals are suit-
able as well, including rats, rabbits, hamsters, guinea pigs,
gerbils, woodchucks, cats, dogs, sheep, goats, pigs, cows,
horses and monkeys (including chimps, gibbons and
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baboons). Assays for inhibitors may be conducted using an
animal model derived from any of these species.
Treatment of animals with test compounds will involve
the administration of the compound, in an appropriate form,
to the animal. Administration will be by any route that could
be utilized for clinical purposes. Determining the effective-
ness of a compound in vivo may involve a variety of
different criteria, including but not limited to alteration of
hypertrophic signaling pathways and physical symptoms of
hypertrophy. Also, measuring toxicity and dose responses
can be performed in animals in a more meaningful fashion
than in vitro or in cyto assays.
Transgenic Animals
A particular embodiment of the present invention pro-
vides transgenic animals that lack one or both functional
alleles of miR-29a, miR-29b, and/or miR-29c. Also, trans-
genic animals that express miR-29a-c underthe control ofan
inducible, tissue selective or a constitutive promoter, recom-
binant cell lines derived from such animals, and transgenic
embryos may be useful in determining the exact role that
miR-29a-c plays in the control of fibrosis and in the devel-
opmentofpathologic cardiac hypertrophy andheart failure.
Furthermore, these transgenic animals may provide an
insight into heart development. The use of an inducible or
repressable miR-29a-c encoding nucleic acid provides a
model for over- or unregulated expression. Also, transgenic
animals that are “knocked out” for miR-29a-c, in one or both
alleles, are contemplated. Also, transgenic animals that are
“knocked out” for miR-29a-c, in one or both alleles for one
or both clusters, are contemplated.
In a general embodiment, a transgenic animalis produced
by the integration of a given transgene into the genomeina
mannerthat permits the expression of the transgene. Meth-
ods for producing transgenic animals are generally described
by Wagner and Hoppe (U.S. Pat. No. 4,873,191; incorpo-
rated herein by reference), and Brinster et al. (1985; incor-
porated herein by reference).
Typically, a gene flanked by genomic sequencesis trans-
ferred by microinjection into a fertilized egg. The microin-
jected eggs are implanted into a host female, and the
progeny are screened for the expression of the transgene.
Transgenic animals may be produced from the fertilized
eggs from a numberof animals including, but not limited to
reptiles, amphibians, birds, mammals, andfish.
DNA clones for microinjection can be prepared by any
means known in the art. For example, DNA clones for
microinjection can be cleaved with enzymes appropriate for
removing the bacterial plasmid sequences, and the DNA
fragments electrophoresed on 1% agarose gels in TBE
buffer, using standard techniques. The DNA bands are
visualized by staining with ethidium bromide, and the band
containing the expression sequences is excised. The excised
bandis then placed in dialysis bags containing 0.3 M sodium
acetate, pH 7.0. DNAis electroeluted into the dialysis bags,
extracted with a 1:1 phenol:chloroform solution and pre-
cipitated by two volumes of ethanol. The DNAis redis-
solved in 1 ml of low salt buffer (0.2 M NaCl, 20 mM Tris,
pH 7.4, and 1 mM EDTA)andpurified on an Elutip-D™
column. The column is first primed with 3 ml of high salt
buffer (1 M NaCl, 20 mM Tris, pH 7.4, and 1 mM EDTA)
followed by washing with 5 ml of low salt buffer. The DNA
solutions are passed through the column three times to bind
DNAto the column matrix. After one wash with 3 ml of low
salt buffer, the DNAis eluted with 0.4 ml high salt buffer and
precipitated by two volumesofethanol. DNA concentrations
are measured by absorption at 260 nm in a UV spectropho-
tometer. For microinjection, DNA concentrations are
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adjusted to 3 ug/ml in 5 mM Tris, pH 7.4 and 0.1 mM EDTA.
Other methods for purification of DNA for microinjection
are described in Palmiter et al. (1982); and in Sambrook et
al. (2001).
In an exemplary microinjection procedure, female mice
six weeks of age are induced to superovulate with a 5 IU
injection (0.1 cc, ip) of pregnant mare serum gonadotropin
(PMSG; Sigma) followed 48 hours later by a 5 IU injection
(0.1 cc, ip) of human chorionic gonadotropin (hCG; Sigma).
Females are placed with males immediately after hCG
injection. Twenty-one hours after hCG injection, the mated
females are sacrificed by C02 asphyxiation or cervical
dislocation and embryos are recovered from excised ovi-
ducts and placed in Dulbecco’s phosphate buffered saline
with 0.5% bovine serum albumin (BSA; Sigma). Surround-
ing cumulus cells are removed with hyaluronidase (1
mg/ml). Pronuclear embryos are then washed andplaced in
Earle’s balancedsalt solution containing 0.5% BSA (EBSS)
in a 37.5° C. incubator with a humidified atmosphere at 5%
CO,, 95% air until the time of injection. Embryos can be
implanted at the two-cell stage.
Randomly cycling adult female mice are paired with
vasectomized males. C57BL/6 or Swiss mice or other com-
parable strains can be used for this purpose. Recipient
females are mated at the same time as donor females. At the
time of embryotransfer, the recipient females are anesthe-
tized with an intraperitoneal injection of 0.015 ml of 2.5%
avertin per gram of body weight. The oviducts are exposed
by a single midline dorsal incision. An incision is then made
through the body wall directly over the oviduct. The ovarian
bursa is then torn with watchmakers forceps. Embryos to be
transferred are placed in DPBS (Dulbecco’s phosphate buff-
ered saline) and in thetip of a transfer pipet (about 10 to 12
embryos). The pipet tip is inserted into the infundibulum and
the embryos transferred. After the transfer, the incision is
closed by two sutures.
DEFINITIONS
As used herein, the term “heart failure” is broadly used to
mean any condition that reduces the ability of the heart to
pump blood. Asa result, congestion and edema develop in
the tissues. Most frequently, heart failure is caused by
decreased contractility of the myocardium, resulting from
reduced coronary blood flow; however, many other factors
mayresult in heart failure, including damage to the heart
valves, vitamin deficiency, and primary cardiac muscle
disease. Though the precise physiological mechanisms of
heart failure are not entirely understood, heart failure is
generally believed to involve disorders in several cardiac
autonomic properties, including sympathetic, parasympa-
thetic, and baroreceptor responses. The phrase “manifesta-
tionsofheart failure”is used broadly to encompassall of the
sequalae associated with heart failure, such as shortness of
breath, pitting edema, an enlarged tender liver, engorged
neck veins, pulmonary rales and the like including labora-
tory findings associated with heart failure.
The term “treatment” or grammatical equivalents encom-
passes the improvementand/orreversal of the symptoms of
heart failure (i.e., the ability of the heart to pump blood).
“Improvementin the physiologic function”ofthe heart may
be assessed using any of the measurements described herein
(e.g., measurement of ejection fraction, fractional shorten-
ing, left ventricular internal dimension, heart rate, etc.), as
well as any effect upon the animal’s survival. In use of
animal models, the response of treated transgenic animals
and untreated transgenic animals is compared using any of
20
25
40
45
55
44
the assays described herein (in addition, treated and
untreated non-transgenic animals may be included as con-
trols). A compound which causes an improvement in any
parameter associated with heart failure used in the screening
methodsofthe instant invention maythereby be identified as
a therapeutic compound.
The term “dilated cardiomyopathy” refers to a type of
heart failure characterized by the presence of a symmetri-
cally dilated left ventricle with poor systolic contractile
function and, in addition, frequently involves the right
ventricle.
The term “compound”refers to any chemical entity,
pharmaceutical, drug, and the like that can be used to treat
or prevent a disease, illness, sickness, or disorder of bodily
function. Compounds comprise both known and potential
therapeutic compounds. A compound can be determined to
be therapeutic by screening using the screening methods of
the present invention. A “known therapeutic compound”
refers to a therapeutic compoundthat has been shown(e.g.,
through animaltrials or prior experience with administration
to humans) to be effective in such treatment. In other words,
a knowntherapeutic compoundis not limited to a compound
efficacious in the treatment of heart failure.
As used herein, the term “cardiac hypertrophy”refers to
the process in which adult cardiac myocytes respond to
stress through hypertrophic growth. Such growth is charac-
terized by cell size increases without cell division, assem-
bling of additional sarcomeres within the cell to maximize
force generation, and an activation of a fetal cardiac gene
program. Cardiac hypertrophy is often associated with
increased risk of morbidity and mortality, and thus studies
aimed at understanding the molecular mechanismsof car-
diac hypertrophy could have a significant impact on human
health.
As used herein, the term “modulate” refers to a change or
an alteration in a biological activity. Modulation may be an
increase or a decrease in protein activity, a change in kinase
activity, a change in binding characteristics, or any other
changein the biological, functional, or immunological prop-
erties associated with the activity of a protein or other
structure of interest. The term “modulator” refers to any
molecule or compound which is capable of changing or
altering biological activity as described above.
The term “f-adrenergic receptor antagonist” refers to a
chemical compound or entity that is capable of blocking,
either partially or completely, the beta (6) type of adreno-
receptors (i.e., receptors of the adrenergic system that
respond to catecholamines, especially norepinephrine).
Some £-adrenergic receptor antagonists exhibit a degree of
specificity for one receptor subtype (generally B,); such
antagonists are termed “f,-specific adrenergic receptor
antagonists” and “B,-specific adrenergic receptor antago-
nists. “ The term B-adrenergic receptor antagonist” refers to
chemical compounds that are selective and non-selective
antagonists. Examples of B-adrenergic receptor antagonists
include, but are not limited to, acebutolol, atenolol, butox-
amine, carteolol, esmolol, labetolol, metoprolol, nadolol,
penbutolol, propanolol, and timolol. The use of derivatives
of known (-adrenergic receptor antagonists is encompassed
by the methods of the present invention. Indeed any com-
pound, which functionally behaves as a B-adrenergic recep-
tor antagonist is encompassed by the methodsof the present
invention.
The terms “angiotensin-converting enzyme inhibitor” or
“ACEinhibitor” refer to a chemical compoundorentity that
is capable of inhibiting, either partially or completely, the
enzyme involved in the conversion oftherelatively inactive
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angiotensin I to the active angiotensin II in the renin-
angiotensin system. In addition, the ACE inhibitors con-
comitantly inhibit the degradation of bradykinin, which
likely significantly enhances the antihypertensive effect of
the ACE inhibitors. Examples ofACE inhibitors include, but
are not limited to, benazepril, captopril, enalopril, fosinopril,
lisinopril, quiapril and ramipril. The use of derivatives of
known ACEinhibitors is encompassed by the methodsofthe
present invention. Indeed any compound, which function-
ally behaves as an ACE inhibitor, is encompassed by the
methods of the present invention.
As used herein, the term “genotypes”refers to the actual
genetic make-up of an organism, while “phenotype”refers
to physicaltraits displayed by an individual. In addition, the
“phenotype” is the result of selective expression of the
genome(1.e., it is an expression of the cell history and its
response to the extracellular environment). Indeed, the
human genomecontains an estimated 30,000-35,000 genes.
In each cell type, only a small (1.e., 10-15%)fraction ofthese
genes are expressed.
The use of the word “a”or “an” when used in conjunction
with the term “comprising” in the claims and/or the speci-
fication may mean “one,” but it is also consistent with the
meaning of “one or more,” “at least one,” and “one or more
than one.”
It is contemplated that any embodiment discussed herein
can be implemented with respect to any method or compo-
sition of the invention, and vice versa. Furthermore, com-
positions and kits of the invention can be used to achieve
methods of the invention.
Throughout this application, the term “about” is used to
indicate that a value includes the standard deviation of error
for the device or method being employed to determine the
value.
The use of the term “or” in the claims is used to mean
“and/or” unless explicitly indicated to refer to alternatives
only or the alternatives are mutually exclusive, although the
disclosure supports a definition that refers to only alterna-
tives and “and/or.”
As used in this specification and claim(s), the words
“comprising” (and any form of comprising, such as “com-
prise” and “comprises”), “having” (and any form of having,
such as “have” and “has”), “including” (and any form of
including, such as “includes” and “include”) or “containing”
(and any form of containing, such as “contains” and “con-
tain”) are inclusive or open-ended and do not exclude
additional, unrecited elements or methodsteps.
Although section headers have been inserted into this
application to facilitate review, such headers should not be
construed as a division of embodiments.
The following examples are included to further illustrate
various aspects of the invention.It should be appreciated by
those of skill in the art that the techniques disclosed in the
examples which follow represent techniques and/or compo-
sitions discovered by the inventor to function well in the
practice of the invention, and thus can be considered to
constitute preferred modes for its practice. However, those
of skill in the art should, in light of the present disclosure,
appreciate that many changes can be made in the specific
embodiments which are disclosed andstill obtain a like or
similar result without departing from the spirit and scope of
the invention.
EXAMPLES
Encoded within an intron of the a-MHC gene is miR-208
(FIG. 1, panel A). Like a-MHC, miR-208 is expressed
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specifically in the heart with trace expression in the lung
(FIG. 1, panel B). miR-208 is processed out of the a-MHC
pre-mRNArather than being transcribed as a separate tran-
script. Intriguingly, however, miR-208 displays a remark-
ably long half-life of at least 14 days, and can thereby exert
functions even when a-MHC mRNA expression has been
down-regulated. Although genetic deletion of miR-208 in
micefailed to induce an overt phenotype, microarray analy-
sis on hearts from wild-type and miR-208-~ animals at 2
months of age revealed removal of miR-208 to result in
pronounced expression of numerous fast skeletal muscle
contractile protein genes, which are normally not expressed
in the heart. Thus, these results suggest that under normal
conditions miR-208 is co-expressed with the sole cardiac-
specific MHC gene to maintain cardiomyocyte identity by
repressing the expression of skeletal muscle genes in the
heart.
The most remarkable function of miR-208 was revealed
by the aberrant response of miR-208-null mice to cardiac
stress (van Rooy et al., 2007). In response to pressure
overload by thoracic aortic constriction or signaling by
calcineurin, a calcium/calmodulin-dependent phosphatase
that drives pathological remodeling of the heart, miR-208-
null mice showedvirtually no hypertrophy of cardiomyo-
cytes or fibrosis and were unable to up-regulate B-MHC
expression (FIGS. 6-8). In contrast, other stress responsive
genes, such as those encoding ANF and BNP, were strongly
induced in miR-208 mutant animals, demonstrating that
miR-208 is dedicated specifically to the control of B-MHC
expression, which can be uncoupled from other facets of the
cardiac stress response.
B-MHCexpression is repressed by thyroid hormonesig-
naling and is up-regulated in the hypothyroid state (Leung et
al., 2006). miR-208-" animals were also resistant to up-
regulation of B-MHC expression following treatment with
the T3 inhibitor propylthiouracil (PTU), which induces
hypothyroidism. Intriguingly, however, expression of
B-MHCbefore birth was normal in miR-208 mutant mice,
indicating that miR-208 is dedicated specifically to the
post-natal regulation of B-MHC expression, which coincides
with the acquisition of thyroid hormone responsiveness of
the B-MHC gene(FIG.5).
A clue to the mechanism of action of miR-208 comes
from the resemblance of miR-208~~ hearts to hyperthyroid
hearts, both of which display a block to B-MHCexpression,
up-regulation of stress-response genes and protection
against pathological hypertrophy andfibrosis (FIGS. 6-10).
The up-regulation of fast skeletal muscle genes in miR-
208-- hearts also mimics the induction of fast skeletal
muscle fibers in the hyperthyroid state (Wei et al., 2005).
These findings suggest that miR-208 acts, at least in part,
by repressing expression of a common componentofstress-
response and thyroid hormone signaling pathways in the
heart. Amongthe strongest predicted targets of miR-208 is
the thyroid hormonereceptor (TR) co-regulator THRAP1,
which can exert positive and negative effects on transcrip-
tion (Pantos et al., 2006; Yao and Eghbali, 1992; FIG. 12).
The TR acts through a negative thyroid hormone response
element (TRE) to repress B-MHC expression in the adult
heart (Zhao et al., 2005). Thus, the increase in THRAP1
expression in the absence of miR-208 would be predicted to
enhance the repressive activity of the TR toward B-MHC
expression, consistent with the blockade to B-MHC expres-
sion in miR-208-hearts. However, although THRAP1
appears to be a bonefide target for miR-208, these data do
not exclude the potential involvementofadditionaltargets in
the regulation of B-MHC expression.
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Since even a subtle shift towards B-MHC reduces
mechanical performanceandefficiency of the adult heart, it
would be of therapeutic value to exploit miR-208 regulation
to prevent an increase in B-MHCexpression during cardiac
disease. The cardiac specificity and dedication of miR-208
to the cardiac stress response, but not to normal cardiac
development, make miR-208 (and its down-stream effec-
tors) an attractive therapeutic target for manipulating
B-MHClevels (FIG. 13).
Materials and Methods
Northern blot analysis. Cardiac tissue samples of left
ventricles of anonymous humans diagnosed as having non-
failing or failing hearts were obtained from Gilead Colorado
(Westminster, Colo.). Cardiac tissue samples of border zone
regions of anonymous humansdiagnosed as having suffered
a myocardial infarction were obtained. Total RNA was
isolated from cells, mouse, rat and human cardiac tissue
samples or isolated myocytes by using Trizol reagent
(Gibco/BRL). Equal loading was confirmed by staining
Northern gels with ethidium bromide. Northern blots to
detect microRNAs were performed as described previously
(van rooy et al., 2006). A U6 probe served as a loading
control. To detect a-MHC expression, a Northern blot
containing 10 ug of RNA from cardiac tissue of both adult
wild-type and miR-208 mutant animals was probed with a
cDNA fragment of a-MHC covering a part of the S'UTR
region andfirst exon.
PTUtreatment. Thyroid hormonedeficiency was induced
by feeding animals for the indicated durations with iodine-
free chow supplemented with 0.15% PTU purchased from
Harlan Teklad Co. (TD 97061) (Madison, Wis.).
Microarray and real-time PCR analysis. Total RNA from
cardiac tissue was isolated using Trizol (Invitrogen).
Microarray analysis was performed using Mouse Genome
430 2.0 array (Affymetrix). To detect the level of miRNA,
RI-PCR was performed using the Taqman MicroRNA
reverse Transcriptase kit (Applied Biosystems, ABI) accord-
ing to the manufacturer’s recommendations. Five ng of
RNA was used to generate cDNA with a miRNAspecific
primer, after which a miRNAspecific Taqman probe served
to detect the expression level of the miRNA of interest.
Following RT-PCR with random hexamerprimers (Invitro-
gen) on RNA samples, the expression of a subset of genes
was analyzed by either PCR or quantitative real time PCR
using Taqman probes purchased from ABI.
Generation of miR-208 mutant mice. To generate the
miR-208 targeting vector, a 0.4 kb fragment(5' arm) extend-
ing upstream of the miR-208 coding region was digested
with SacI] and NotI and ligated into the pGKneoF2L2dta
targeting plasmid upstream of the loxP sites and the Frt-
flanked neomycin cassette. A 3.3 kb fragment (3' arm) was
digested with SalI and HindIII and ligated into the vector
between the neomycin resistance and Dta negative selection
cassettes. Targeted ES-cells carrying the disrupted allele
were identified by Southern blot analysis with 5' and 3'
probes. Three miR-208 targeted ES clones were identified
and used for blastocyst injection. The resulting chimeric
mice were bred to C57BL/6 to obtain germline transmission
of the mutant allele.
Generation of transgenic mice. A mouse genomic frag-
ment flanking the miRNA of interest was subcloned into a
cardiac-specific expression plasmid containing the a-MHC
and human GH poly(A)+ signal (Kiriazis and Kranias,
2000). Genomic DNA wasisolated from mousetail biopsies
and analyzed by PCR using primers specific for the human
GH poly(A)+ signal.
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Western blotting. Myosin was extracted from cardiac
tissue as described (Morkin, 2000). MHC isoforms were
separated by SDS PAGE and Western blotting was per-
formed with mouse monoclonal a-MHC (BA-G5) (ATCC,
Rockville, Md.) and mouse monoclonal antimyosin (slow,
skeletal M8421) (Sigma, Mo.), which is highly specific for
B-MHC.To detectall striated myosin a pan specific antibody
(mouse monoclonal 3-48; Accurate Chemical & Scientific
Corporation, NY) was used. THRAP1 was detected by
immunoprecipitation from 400 ug of cardiac protein lysate.
After pre-clearing the samples for 1 hour at 4° C., the
supernatant was incubated overnight at 4° C. with 1 ul rabbit
polyclonal anti-THRAP1 (a kind gift of R. Roeder, Rock-
efeller University) and 15 ul of protein A beads. The beads
were washedthree times with lysis buffer and boiled in SDS
sample buffer. Immunoprecipitated THRAP1 protein was
resolved by SDS-PAGE and analyzed using rabbit poly-
clonal anti-THRAP1 at a dilution of 1:3000 and anti-rabbit
IgG conjugated to horseradish peroxidase at a dilution of
1:5000 with detection by Luminol Reagent (Santa Cruz).
Histological analysis and RNA In situ hybridization.
Tissues used for histology were incubated in Krebs-Hensel-
heit solution, fixed in 4% paraformaldehyde, sectioned, and
processed for hematoxylin and eosin (H&E) and Masson’s
Trichrome staining or in situ hybridization by standard
techniques (Krenz and Robbins, 2004). *°S-labeled RNA
probes were generated using Maxiscript kit (Amersham).
Signals were pseudocolored in red using Adobe Photoshop.
Transthoracic echocardiography. Cardiac function and
heart dimensions were evaluated by two-dimensional
echocardiography in conscious mice using a Vingmed Sys-
tem (GE Vingmed Ultrasound, Horten, Norway) and a
11.5-MHz linear array transducer. M-mode tracings were
used to measure anterior and posterior wall thicknesses at
end diastole and end systole. Left ventricular (LV) internal
diameter (LVID) was measuredasthe largest anteroposterior
diameter in either diastole (LVIDd)or systole (LVIDs). The
data were analyzed by a single observer blinded to mouse
genotype. LV fractional shortening (FS) was calculated
according to the following formula: FS (%)=[(LVIDd-
LVIDs)/LVIDd]x100.
Plasmids and transfection assays. A 305 bp genomic
fragment encompassing the miR-208 coding region was
amplified by PCR andligated into pCMV6. A 1 kb fragment
encompassing the entire murine THRAP1-UTR was PCR-
amplified and ligated into an HA-tagged pCMV6expression
construct andthe firefly luciferase (f-luc) reporter construct
(pMIR-REPORT™, Ambion). A mutation of the UCGUC-
UUA miR-208 seed binding sequence was constructed
through PCR-based mutagenesis.
Cell culture, transfection and luciferase assays. A 1793-bp
genomic fragment encompassing miR-29b-1 and miR-29a
coding region was amplified by PCR and ligated into
pCMV6. Genomic fragments of the murine 3' UTR encom-
passing the miR-29a-c binding site(s) were PCR-amplified
and ligated into the firefly luciferase (f-luc) reporter con-
struct (pMIR-REPORT™ Ambion). COS cells were trans-
fected with Fugene 6 (Stratagene) according to manufactur-
er’s instructions. The total amount of DNAper well was kept
constant by adding the corresponding amount of expression
vector without a cDNAinsert. 48 hours after transfection,
cell extracts were assayed for luciferase expression using the
luciferase assay kit (Promega). Relative promoter activities
are expressed as luminescencerelative units normalized for
6-galactosidase expression in the cell extracts.
Cardiac fibroblasts (CFs) were isolated as described pre-
viously (Simpson and Savion, 1982). Briefly, hearts were
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excised from anesthetized neonatal 1-2 day-old Sprague-
Dawley rats (Harlan Sprague Dawley, Indianapolis, Ind.),
minced, and digested with pancreatin 0.1%. Cells were
plated on primaria plates for 2 h, and the medium which
contained the cardiomyocyte fraction of the digested tissue
was removed. Cardiac fibroblasts attached and proliferated
much more rapidly than cardiac myocytes; this produced
virtually pure fibroblast cultures after the first passage,
which was confirmed by repeated differential plating and
microscopic evaluation. Cells were detached with 0.05%
trypsin for passaging, and culture studies were performed at
passages 2 to 4. Cells were grownin high glucose (4.5 gm/It)
Dulbecco’s modified Eagle’s medium (DMEM) containing
10% heat-inactivated FBS and antibiotics (Penicillin and
streptomycin). Myofibroblast differentiation was induced by
changing the medium to low serum (2% FBS) with L-ascor-
bic acid (10 g/1) and administration of 10 ng/ml TGFB1 for
48 hours.
In vivo miR-29b silencing by anti-miR treatment. Chemi-
cally modified antisense oligonucleotides comprising a
sequence complementary to miR-29b (anti-miR-29b) were
used to inhibit miR-29b expression. All bases were 2'-OMe
modified, the first two and last four bases contained a
phosphorothioate internucleoside bond andthe 3' end of the
oligonucleotides was conjugated to cholesterol. Eight week-
old C57BL/6 male mice received either anti-miR-29b
(AsAsCACUGAUUUCAAAUGGUSsGsCsUsAs-Choles-
terol) or mismatch miR-29b (AsAsAACUGAUGUCA-
CAUGGUsGsAsUsAs-Cholesterol) at a dose of 80 mg/kg
body weight or a comparable volumeofsaline through tail
vein injection. Tissues were collected either 3 days or 3
weeks after treatment.
Example 1
Regulation of Cardiac Hypertrophy and Heart
Failure by Stress-responsive miRNAs
In light of their involvement in modulating cellular phe-
notypes, the inventors hypothesized that miRNAs may play
arole in regulating the responseofthe heart to cardiac stress,
which is knownto result in transcriptional and translational
changes in gene expression. To investigate the potential
involvement of miRNAs in cardiac hypertrophy, they per-
formed a side-by-side miRNA microarray analysis in 2
established mouse models of cardiac hypertrophy, using a
microarray that represented 186 different miRNAs (Babak et
al., 2004). Mice that were subjected to thoracic aortic
banding (TAB), which induces hypertrophy by increased
afterload on the heart (Hill et al., 2000), were compared to
sham operated animals. In a second model, transgenic mice
expressing activated calcineurin (CnA) in the heart, which
results in a severe, well-characterized form of hypertrophy
(Molkentin et al., 1998), were compared to wild-typelitter-
mates (FIG. 14A). RNA isolated from hearts of mice sub-
jected to TAB showedincreased expression of 27 miRNAs
compared to sham-operated controls, and CnA Tg mice
showedincreased expression of 33 miRNAs compared with
non-transgenic littermate controls, of which 21 were up-
regulated in both models. Similarly, TAB and CnA-induced
hypertrophy were accompanied by reduced expression of 15
and 14 miRNAs, respectively, of which 7 miRNAs were
down-regulated in common (FIG. 14B). Northern analysis
of these miRNAs (unpublished data) and previous microar-
ray analyses (Barad et al., 2004; Sempere et al., 2004;
Shingara et al., 2005; Liu et al., 2004) indicate that they are
expressed in a wide range of tissues. Based ontheirrelative
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expression levels, conservation of human, rat and mouse
sequences, and levels of expression during hypertrophy, the
inventors focused on 11 up- and 5 down-regulated miRNAs
(FIG. 14C).
Northern blot analysis of cardiac RNA from WT and CnA
Tg animals confirmed an increased expression of miRs-21,
-23, -24, -125b, -195, -199a, and -214, and decreased
expression of miRs-29, -93, -150 and -181b (FIG. 14C and
FIG. 15). Collectively, these data indicate that distinct
miRNAsare regulated during cardiac hypertrophy, suggest-
ing the possibility that they function as modulators of this
process.
Example 2
Discovery of the miR-29 Family as Down-stream
Targets for Regulation by miR-208
The inventors performed a miRNA microarray on hearts
from wild-type and miR-208-null mice in an effort to
identify downstream miRNAsthat might mediate the actions
of miR-208 (FIG. 16). They discovered that multiple mem-
bers of the miR-29 family were up-regulated in miR-208-
null mice (FIG. 17). Target prediction indicated that miR-29
family members targeted mRNAs encoding multiple colla-
gens and other componentsofthe extracellular matrix (FIG.
18). Thus, the up-regulation of miR-29 family members in
miR-208-null mice is likely to account for the block to
fibrosis seen in these animals (FIG. 19).
The discovery that miR-29a-c is down-regulated in the
diseased heart and targets mRNAs encoding collagens and
extracellular matrix proteins suggests that strategies to
enhance expression of miR-29a-c or its association with
target mRNAscan have beneficial effects on the heart in the
settings of pathological cardiac remodeling and fibrosis.
Moreover, elevation of miR-29a-c expression or function
may prevent fibrosis associated with many diseases in
tissues such as skeletal muscle, liver, lung, kidney and
others. In addition, the discovery that miR-208 represses
miR-29a-c expression, and that loss ofmiR-208 upregulates
miR-29a-c expression, indicates that miR-29a-c is a down-
stream mediator of the actions of miR-208 on the heart.
Example 3
MiR-29a-c regulates the Expression of Fibrotic
Genes
To begin to define the possible functions for miR-29a-c in
the heart following MI, the inventors made use of compu-
tational predictions to identify possible miR-29a-c targets.
The Targetscan prediction website indicated an unexpect-
edly high numberoffibrosis-related mRNAsencoding col-
lagens, metallopeptidases, and integrins as possible targets
for miR-29a-c (word-wide web at targetscan.org). To deter-
mine whether the downregulation ofmiR-29a-c might regu-
late cardiac fibrosis, the inventors focused on predicted
targets implicated in ECM production in heart. Elastin
(ELN), fibrillin 1 (FBN1), collagen type I, al and a2
(COL1A1, COL1A2) and collagen type HI, al (COL3A1) all
contain one or more conserved potential seed sequences for
miR-29a-c (FIG. 20A).
Because miRNAs down-regulate the steady state levels,
as well as the translation, of their target mRNAs, the
inventors analyzed the expression of predicted miR-29a-c
mRNAtargets. Real-time RT-PCR analysis of these key
regulatory genes for cardiac fibrosis in cardiac samples 3
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days after MI indicated that the specific downregulation of
miR-29a-c in the infracted region correlates with the
increase in expression of COL1A1, COL1A2, COL3A1, and
FBN1. In contrast, ELN appeared unchanged in the border
zone, and even showed an increase in the remote myocar-
dium (FIG. 20B).
Using a CMV-driven expression plasmid, the inventors
overexpressed miR-29b-1 and miR-29a in COScells (FIG.
20C) with luciferase expression plasmids containing the
3'-UTRs of the predicted miR-29a-c targets. Increasing
amounts of CMV-driven miR-29b-1/miR-29a resulted in a
dose-dependent decrease in luciferase activity, while com-
parable amounts of miR-206, as a control, had no effect
(FIGS. 20C-D), substantiating these mRNAsastargets for
repression by miR-29a-c.
Example 4
Regulation of miR-29a-c in Cardiac Fibroblasts
Cardiac fibrosis is a major aspect of the remodeling
process typically seen in the failing heart. The proliferation
of fibroblasts and increased deposition of ECM components
results in myocardial stiffness and diastolic dysfunction.
Transforming growth factor B (TGFB) has been shown to
play a dominant role in the production and deposition of
collagens in the heart and induces a transformation of
fibroblasts into myofibroblasts (Border and Noble, 1994).
Real-time PCR analysis on cardiac fibroblasts exposed to
TGFB revealed a decrease in miR-29a-c expression, sug-
gesting that the decrease in miR-29a-c following MI might
be TGFp-regulated (FIG. 21A). Interestingly, natriuretic
peptides like B-type natriuretic peptide (BNP) have been
shown to inhibit TGFB-regulated gene expression related to
fibrosis and myofibroblast conversion (Kapounetal., 2004).
In this regard, the inventors reported previously that mice
lacking the cardiac-specific miRNA miR-208 wereresistant
to cardiac fibrosis and remodeling and exhibited increased
expression of BNPat baseline (van Rooij et al., 2007). Since
BNP is known to antagonize the effects of TGF, the
inventors speculated that the increased levels of BNP in
these mice might enhance the expression of miR-29a-c.
Indeed, Northern analysis showed a dose-dependent
increase in miR-29a-c expression upon removal ofmiR-208,
which coincided with an increasing expression level of BNP
(FIG. 21B). These data indicate that TGF induces the
expression of collagen related genes in fibroblasts at least
partly through decreasing the level of miR-29a-c, which can
be inhibited by BNP secreted by cardiomyocytes.
Example 5
In Vivo Knockdown of miR-29a-c Induces Fibrosis
and Expression of Collagen Genes
To further explore the potential role of miR-29a-c as a
negative regulator of collagen expression, the inventors
knocked down miR-29b in vivo using cholesterol-modified
oligonucleotides complementary to the mature miRNA
sequence of miR-29b (anti-miR-29b) andeither saline or an
oligonucleotide containing a four-base mismatch (mm miR-
29b) as a negative control (FIG. 22A). Three days after a
single tail vein injection of anti-miR-29b (80 mg/kg), the
inventors observed a dramatic diminution of miR-29b
expression in all tissues examined (FIG. 22B). In contrast, a
comparable dose of the mm miR-29b antisense oligonucle-
otide had no effect on the expression level of miR-29b
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compared to the saline control. Knockdown by anti-miR-
29b appeared to be specific to the mature miRNA,since the
level ofpre-miRNA remained comparable between anti-miR
and mm treated animals. While the knockdown inthe liver
and kidney appeared to be complete, a low level ofmiR-29b
remained detectable in the heart and lung (FIG. 22B).
Since the other miR-29 members share high sequence
homology with miR-29b, the expression of miR-29a and -c
in response to anti-miR-29b was also examined. While a
significant knockdown in liver and kidney (especially for
miR-29c), was detected, cardiac expression did not appear to
change (FIG. 23). Real-time PCR analysis indicated that
miR-29b knockdownwassufficient to induce the expression
of collagen genes in the liver specifically, while this effect
was absent in the mismatch controls (FIG. 22C).
To enhance cardiac knockdown ofmiR-29b, the inventors
injected 80 mg/kg of oligonucleotide intravenously on two
consecutive days and collected material 3 weeks later.
Northern analysis indicated complete knockdown of miR-
29b in kidney and liver in response to anti-miR-29b com-
pared to the expression level seen after mm miR-29b injec-
tion. Cardiac levels of miR-29b were also dramatically
reduced, while the expression of miR-29b in lung appeared
unaffected by anti-miR-29b (FIG. 22D). Collagen expres-
sion in the heart was increased in response to miR-29b
inhibition (FIG. 22E). Taken together, these data indicate
that miR-29b functions as a negative regulator of collagen
gene expression in vivo and thereby influences collagen
deposition and fibrosis in the heart andliver.
Example 6
Down-regulation of Collagen Expression with a
miR-29a-c Mimic
To determine whether overexpression of miR-29a-c was
capable of reducing collagen expression, the inventors
exposed fibroblasts to a miR-29b mimic. The level of
miR-29b expression in fibroblasts cultures increased by as
much as 400-fold after 3 days ofexposure to miR-29b mimic
(FIG. 22F). miR-29a expression was unaffected and miR-
29¢ expression was increased only slightly by miR-29b
mimic (FIG. 22F). Real-time PCR analysis indicated that the
expression of collagen genes was diminished in response to
miR-29b mimic (FIG. 22G). However, the magnitude of the
decrease in collagen expression was modest comparedto the
increase in expression of miR-29b, indicating that miR-
29a-c levels are not the sole determinant of collagen levels.
oe ok ok
All publications, patents and patent applications discussed
and cited herein are incorporated herein by reference in their
entireties. All of the compositions and methods disclosed
and claimed herein can be made and executed without undue
experimentation in light of the present disclosure. While the
compositions and methods of this invention have been
described in terms of preferred embodiments, it will be
apparent to those of skill in the art that variations may be
applied to the compositions and methods, andin the steps or
in the sequence of steps of the methods described herein
without departing from the concept, spirit and scope of the
invention. More specifically, it will be apparent that certain
agents which are both chemically and physiologically
related may be substituted for the agents described herein
while the same or similar results would be achieved. All
such similar substitutes and modifications apparent to those
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skilled in the art are deemedto be withinthespirit, scope and
concept of the invention as defined by the appended claims.
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SEQUENCE LISTING
<160> NUMBER OF SEQ ID NOS: 22
<210>
<211>
<212>
<213>
SEQ ID NO 1
LENGTH: 71
TYPE: DNA
ORGANISM: Homo sapiens
<400> SEQUENCE: 1
tgacgggega gettttggee cgggttatac ctgatgctca cgtataagac gagcaaaaag
cttgttggtc a
<210> SEQ ID NO 2
60
71
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<211>
<212>
<213>
<400>
LENGTH: 71
TYPE: DNA
ORGANISM: Mus sp.
SEQUENCE: 2
tgacgggtga gettttggce cgggttatac ctgactctca cgtataagac gagcaaaaag
ettgttggte a
<210>
<211>
<212>
<213>
<400>
SEQ ID NO 3
LENGTH: 71
TYPE: DNA
ORGANISM: Rattus sp.
SEQUENCE: 3
tgacgggtga gettttggce cgggttatac ctgactctca cgtataagac gagcaaaaag
ettgttggte a
<210>
<211>
<212>
<213>
<400>
SEQ ID NO 4
LENGTH: 71
TYPE: DNA
ORGANISM: Canis sp.
SEQUENCE: 4
tgacgeatga gcettttggct cgggttatac ctgatgetca cgtataagac gagcaaaaag
ettgttggte a
<210>
<211>
<212>
<213>
<220>
<223>
<400>
SEQ ID NO 5
LENGTH: 22
TYPE: RNA
ORGANISM: Unknown
FEATURE:
OTHER INFORMATION: miR-208 sequence
SEQUENCE: 5
auaagacgag caaaaagecuu gu
<210>
<211>
<212>
<213>
<400>
SEQ ID NO 6
LENGTH: 69
TYPE: RNA
ORGANISM: Homo sapiens
SEQUENCE: 6
uucuugcuuu aaagcaauug gucuaaaaua uauguaaucg ucuuaauuaa aaaguugcag
uaggguuge
<210>
<211>
<212>
<213>
<400>
SEQ ID NO 7
LENGTH: 69
TYPE: RNA
ORGANISM: Pan sp.
SEQUENCE: 7
uucuugcuuu aaagcaauug gucuaaaaua uauguaaucg ucuuaauuaa aacguugcag
uaggguuge
<210>
<211>
<212>
<213>
<400>
SEQ ID NO 8
LENGTH: 69
TYPE: RNA
ORGANISM: Mus sp.
SEQUENCE: 8
uucuugcuuu aaagcaauug gucuaaaaua uauguaaucg ucuuaauuaa aacguugcag
60
71
60
71
60
71
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60
69
60
69
60
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uaggguuge
<210> SEQ ID NO 9
<211> LENGTH: 69
<212> TYPE: RNA
<213> ORGANISM: Rattus sp.
<400> SEQUENCE: 9
uucuugcuuu aaagcaauug gucuaaaaua uauguaaucg ucuuaauuaa aacguugcag
uaggguuge
<210> SEQ ID NO 10
<211> LENGTH: 69
<212> TYPE: RNA
<213> ORGANISM: Canis sp.
<400> SEQUENCE: 10
uucuugcuuu aaagcaauug gucuaaaaua uauguaaucg ucuuaauuaa aacguugcag
uaggguuge
<210> SEQ ID NO 11
<211> LENGTH: 69
<212> TYPE: RNA
<213> ORGANISM: Gallus sp.
<400> SEQUENCE: 11
uucuugcuuu aaagcaauug gucuaaaaua uauguaaucg ucuuaauuaa aacguugcag
uaggguuge
<210>
<211>
<212>
<213>
SEQ ID NO 12
LENGTH: 72
TYPE: RNA
ORGANISM: Takifugu
<400> SEQUENCE: 12
uuccugcuuu aagcaauugg uugaaaauau auguauguaa uggucuuaau uaaaaaaaca
aacuaagaca aa
<210> SEQ ID NO 13
<211> LENGTH: 69
<212> TYPE: RNA
<213> ORGANISM: Danio sp.
<400> SEQUENCE: 13
uuccugcuuu aaagcaauug gucuaaaaua uauguaaucg ucuucauuac aaaaacgaac
caucaaacg
<210> SEQ ID NO 14
<211> LENGTH: 71
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 14
acegggegage ttttggeccg ggttatacct gatgetcacg tataagacga gcaaaaaget
tgttggtcag a
<210> SEQ ID NO 15
<211> LENGTH: 71
<212> TYPE: DNA
69
60
69
60
69
60
69
60
72
60
69
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71
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<213>
<400>
ORGANISM: Mus sp.
SEQUENCE: 15
acgggtgage ttttggceccg ggttatacct gactctcacg tataagacga gcaaaaaget
tgttggtcag a
<210>
<211>
<212>
<213>
<400>
SEQ ID NO 16
LENGTH: 71
TYPE: DNA
ORGANISM: Rattus sp.
SEQUENCE: 16
acgggtgage ttttggceccg ggttatacct gactctcacg tataagacga gcaaaaaget
tgttggtcag a
<210>
<211>
<212>
<213>
<400>
SEQ ID NO 17
LENGTH: 71
TYPE: DNA
ORGANISM: Canis sp.
SEQUENCE: 17
acgcatgage ttttggctcg ggttatacct gatgetcacg tataagacga gcaaaaaget
tgttggtcag a
<210>
<211>
<212>
<213>
<400>
SEQ ID NO 18
LENGTH: 22
TYPE: RNA
ORGANISM: Homo sapiens
SEQUENCE: 18
uageaccauc ugaaaucggu ua
<210>
<211>
<212>
<213>
<400>
SEQ ID NO 19
LENGTH: 23
TYPE: RNA
ORGANISM: Homo sapiens
SEQUENCE: 19
uageaccauu ugaaaucagu guu
<210>
<211>
<212>
<213>
<400>
SEQ ID NO 20
LENGTH: 22
TYPE: RNA
ORGANISM: Homo sapiens
SEQUENCE: 20
uageaccauu ugaaaucggu ua
<210>
<211>
<212>
<213>
<220>
<223>
<400>
SEQ ID NO 21
LENGTH: 71
TYPE: RNA
ORGANISM: Unknown
FEATURE:
OTHER INFORMATION: Pre miR-208 sequence
SEQUENCE: 21
ugacgggega gcuuuuggee cggguuauac cugaugcuca cguauaagac gagcaaaaag
cuuguugguc a
<210> SEQ ID NO 22
<211> LENGTH: 27
60
71
60
71
60
71
22
23
22
60
71
US 9,719,088 B2
 
65 66
-continued
<212> TYPE: RNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 22
uagcaccauu ugaaagaaau caguguu 27
The invention claimedis: 10 9. The medical device of claim 1, wherein the sugar
1. Amedical device coated with a formulation comprising
an antisense oligonucleotide comprising a sequencethatis at
least 75% complementary to a miR-29a, miR-29b, and/or
miR-29¢ sequence, wherein the antisense oligonucleotide is
about 15-50 nucleotides in length, and wherein the antisense
oligonucleotide comprises at least one sugar modification or
at least one backbone modification.
2. The medical device of claim 1, wherein the medical
device is a stent or balloon.
3. The medical device of claim 1, wherein the antisense
oligonucleotide comprises a sequence that is at least 75%
complementary to SEQ ID NO: 18, SEQ ID NO: 19, and/or
SEQ ID NO:20.
4. The medical device of claim 3, wherein the antisense
oligonucleotide comprises a sequence that is at least 85%
complementary to SEQ ID NO: 18, SEQ ID NO: 19, and/or
SEQ ID NO:20.
5. The medical device of claim 3, wherein the antisense
oligonucleotide comprises a sequence that is at least 95%
complementary to SEQ ID NO: 18, SEQ ID NO: 19, and/or
SEQ ID NO:20.
6. The medical device of claim 3, wherein the antisense
oligonucleotide comprises a sequence that is 100% comple-
mentary to SEQ ID NO: 18, SEQ ID NO:19, and/or SEQ ID
NO:20.
7. The medical device of claim 1, wherein the antisense
oligonucleotide comprises a sequence that is at least 95%
complementary to a pre-miR-29a, pre-miR-29b, and/or pre-
miR-29¢ sequence.
8. The medical device of claim 1, wherein the antisense
oligonucleotide is about 19 to about 25 nucleotides in length.
15
20
25
30
35
modification is a modification selected from the group
consisting of 2'-O-alkyl, 2'-O-methyl, 2'-O-methoxyethyl,
2'-fluoro, and a locked nucleic acid.
10. The medical device of claim 1, wherein the backbone
modification is a phosphorothioate linkage.
11. The medical device of claim 1, wherein the antisense
oligonucleotide is conjugated to cholesterol at its 3' termi-
nus.
12. The medical device of claim 1, wherein the formula-
tion further comprises an anti-restenosis compound.
13. The medical device of claim 12, wherein the anti-
restenosis compound is paclitaxel, rapamycin, tacrolimus,
zotarolimus, everolimus, docetaxel, pimecrolimus, or
derivatives thereof.
14. The medical device of claim 1, wherein the antisense
oligonucleotide comprises a sequence that is at least 85%
complementary to a miR-29a, miR-29b, and/or miR-29c
sequence.
15. The medical device of claim 1, wherein the antisense
oligonucleotide comprises a sequence that is at least 95%
complementary to a miR-29a, miR-29b, and/or miR-29c
sequence.
16. The medical device of claim 1, wherein the antisense
oligonucleotide comprises a sequence that is 100% comple-
mentary to a miR-29a, miR-29b, and/or miR-29c sequence.
17. The medical device of claim 7, wherein the antisense
oligonucleotide comprises a sequence that is 100% comple-
mentary to a pre-miR-29a, pre-miR-29b, and/or pre-miR-
29¢ sequence.
